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The Role of Monocyte Chemoattractant Protein-1 on Operant Ethanol 
Self-Administration in Long-Evans Rats 
 
John Valenta, PhD 
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Supervisor:  Rueben A. Gonzales 
 
The neuroimmune system can exert a powerful influence over behavior, and 
evidence is mounting that the neuroimmune system can influence the intake of drugs of 
abuse.  Insight into the interaction between drugs of abuse and the neuroimmune system 
will teach us more about the inner workings of the brain and can lead to new treatment 
options for addiction.  Previous research has demonstrated that alcoholics have elevated 
levels of immune signaling molecules. My dissertation project demonstrated that elevating 
immune signaling molecules in the brain can directly increase ethanol consumption.   
 
A variety of cytokines are elevated in human alcoholics and animal models of 
ethanol dependence.  However, recent research has suggested that monocyte 
chemoattractant protein -1 (MCP-1) is particularly important.  Researchers have found 
elevated levels of MCP-1 in the brains of human alcoholics, in animal brains after chronic 
exposure to ethanol, and in brain slices exposed to ethanol.  Also, MCP-1 or MCP-1 
receptor (CCR2) knockout mice had a significant reduction in ethanol consumption and a 




Generally speaking, I accomplished this by increasing the amount of MCP-1 
signaling in the brain and then measuring ethanol drinking behavior.  I infused MCP-1 into 
the cerebral ventricles of rodents for 4 weeks and measured their ethanol intake for those 
4 weeks as well as 4 additional weeks.  There was a significant interaction between dose 
of MCP-1 and ethanol consumed across the first 4 weeks (while pumps were flowing) and 
across the 8-week experiment. Animals receiving the highest dose of MCP-1 (2 µg/day) 
were the highest consumers of ethanol during weeks 3 through 8. 
 
My second goal was to determine how the modulation of brain MCP-1 signaling 
could influence drinking behavior in ethanol-dependent rodents.  I made progress toward 
this goal by reliably reaching target BAC’s in rodents through the use of ethanol vapor 
inhalation chambers, but I did not reach the point of inducing dependence or modulating 
MCP-1. 
 
The neuroimmune system seems to be paramount in the progressive loss of control 
over drug intake seen in drug addiction and presents a potential route for the treatment of 
addiction.  The results of my experiments support this hypothesis by providing evidence 
that neuroimmune signaling can increase ethanol consumption, show that MCP-1 signaling 
is critical in this phenomenon, and identify MCP-1 signaling as a strong candidate for 
investigating the therapeutic potential of neuroimmune signaling for alcohol use disorders.
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Chapter 1: General Introduction 
 
Alcohol abuse and alcohol dependence are among the most widespread and costly 
health concerns in the United States. An estimated 17.6 million American adults (8.5 
percent) are afflicted with one of the two disorders every year (Hasin et al., 2007) with an 
estimated economic cost of $223.5 billion per year (Bouchery et al., 2011). Notably, 30.3 
percent of Americans have been afflicted with it at some point in their life (Hasin et al., 
2007). Like other substance abuse disorders, it can be seen as a progressive loss of 
behavioral control that leads to continued use despite harm. The neurobiological 
mechanisms that contribute to the shift from healthy to unhealthy alcohol consumption are 
complex and mostly undiscovered. With only a few unreliable treatment options available, 
the development of new molecular targets is critical. 
 
Alcohol use disorders (AUD’s) have profound effects on the immune system, 
including the immune system of the brain. There is evidence of an interaction between 
AUD’s and neuroimmune signaling or neuroinflammation, including the following: 
alcoholic human brains have increased amounts of neuroimmune signaling molecules 
(cytokines), increasing neuroimmune signaling leads to increased ethanol consumption in 
animals, and genetically modified mice lacking specific components of their immune 
system tend to drink less ethanol than their counterparts.  
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A variety of cytokines are elevated in human alcoholics and animal models of 
dependence.  However, recent research has suggested that monocyte chemoattractant 
protein -1 (MCP-1) is particularly important.  MCP-1 is a central molecule in the 
inflammatory response and recruits microglia to sites of brain injury (Piao et al., 2008).  
Researchers have found elevated levels of MCP-1 in the brains of human alcoholics, in 
animal brains after chronic exposure to ethanol, and in brain slices exposed to ethanol.  
MCP-1 receptor (CCR2) knockout mice had a robust reduction in ethanol consumption and 
a reduced preference for ethanol (Blednov et al., 2005).  Altogether, this data suggests that: 
MCP-1 signaling is important in the development of drinking behavior of wild-type 
rodents; that enhancing MCP-1 signaling may accelerate the onset of ethanol dependence 
or increase the severity of ethanol dependence; that blocking MCP-1 signaling may blunt 
the development of drinking behavior; and identifies MCP-1 and it’s receptor as potential 
target molecules for therapeutic intervention.  The goal of my dissertation is to test the 
hypothesis that MCP-1-mediated neuroimmune signaling can influence ethanol self-
administration.  
 
Generally speaking, I accomplished this by increasing the amount of MCP-1 
signaling in the brain and then measuring drinking behavior.  There are three phases of 
drinking behavior I investigated.  First, I looked at the acquisition of drinking behavior (i.e. 
an animal that has never drunk before was given a chronic infusion of MCP-1 and I 
measured how fast the animal began to drink and how fast the drinking escalated).  After a 
week or so, the animals generally stabilized their ethanol intake, and I measured if the 
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MCP-1 infusion influenced the average daily intake during “stable” intake for several 
weeks.  Third, I looked at how long the influence on drinking lasted after the MCP-1 
infusion was stopped.   
 
In short, there was a significant interaction between dose of MCP-1 and sweetened 
ethanol consumed across the first 4 weeks (while pumps were flowing) and across the 8-
week experiment. Animals receiving the highest dose of MCP-1 (2 µg/day) were the 
highest consumers of ethanol during weeks 3 through 8. MCP-1 did not influence the 
acquisition of self-administration (measured across the first 5 days), the motivation to 
consume ethanol (time to lever press or progressive ratio), withdrawal-induced anxiety, or 
the consumption of sucrose alone.   
 
The mechanisms influencing ethanol intake during casual drinking compared to 
drinking while dependent on ethanol (i.e. alcoholism) are different, and the influence of 
neuroimmune signaling on each is potentially distinct.  With a variety of research 
suggesting that neuroimmune signaling interacts with ethanol dependence, I also attempted 
to research how the modulation of brain MCP-1 signaling could influence drinking 
behavior in dependent rodents.  In order to induce dependence, I built an ethanol vapor 
inhalation chamber system.  Vapor inhalation has been shown to increase ethanol drinking 
in various strains of rodents.  I have also replicated a common home cage drinking model 
with the goal of using ethanol vapor to influence home cage ethanol intake.  However, the 
rate of alcohol metabolism between individual Long-Evans rats seemed highly variable, 
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and I had some trouble obtaining reliable blood alcohol levels in my rodents using ethanol 
vapor.  However, reliable data was obtained when using 4-methylpyrazole to block ethanol 
metabolism.  I have not yet tested the influence of MCP-1 on drinking behaviors of 
dependent animals.  However, both the home cage drinking data and the vapor inhalation 
data will be presented in this dissertation.   
 
My research has provided novel evidence that neuroimmune signaling can directly 
increase chronic operant ethanol self-administration, and that this increase persists beyond 
the administration of the cytokine. These data suggest that ethanol-induced increases in 
MCP-1, or increases in MCP-1 due to various other neuroimmune mechanisms, may 
further promote ethanol consumption.  By understanding how neuroimmune signaling can 
regulate drinking behavior, we can develop insights into the transition from healthy to 
unhealthy drinking behavior and we can develop new molecular targets for treatment.  
Continued research into the MCP-1 mechanism, particularly using models of ethanol 
dependence, will help determine if targeting MCP-1 signaling has therapeutic potential in 
the treatment of alcohol use disorders. 
 
THE BRAIN’S INNATE IMMUNE SYSTEM 
 
Nervous tissue contains 4 major classes of cells: neurons, astrocytes, 
oligodendrocytes, and microglia.  Neurons are highly specialized cells that are electrically 
excitable and form a complex network of neurotransmitter-based intercellular 
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communication that is the foundation of thoughts and consciousness.  Astrocytes, 
oligodendrocytes, and microglia are collectively referred to as glia or glial cells and are 
generally considered supporting cells for neurons but have specialized responsibilities as 
well.  Oligodendrocytes wrap the axons of neurons in myelin sheaths, helping them 
propagate electrical signals efficiently.  Astrocytes provide mechanical and biochemical 
support to neurons and other cells, including endothelial cells in the brain.  They participate 
in tissue repair mechanisms, ion transport, neurotransmitter uptake and release, and help 
regulate ion concentrations.  Microglia are macrophages that form the basis of the brain’s 
immune system.  They are mobile within the brain and communicate with other cells 
primarily through the secretion of cytokines.     
 
Cytokines are molecules that immune cells use for cell-to-cell communication.  
Chemokines are a type of cytokine that induces chemotaxis of cells up the concentration 
gradient.  For example, MCP-1 is a chemokine that attracts monocytes.  There are dozens 
of chemokines, but only 19 known receptors, all of which are metabotropic, g-protein 
coupled receptors. 
 
The blood-brain barrier (BBB) is a selectively permeable barrier formed by 
endothelial tight-junctions that aids in maintaining a highly specific environment for 
central nervous tissue and helps prevent the spread of infections to the delicate nervous 
tissue.  The BBB is tightly regulated and prevents all but the smallest molecules from 
passively diffusing into the brain parenchyma.  Astrocytes generally wrap around the 
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junctions between endothelial cells, provide biochemical support for the endothelial cells 
and participate in the transport of molecules across the barrier, but evidence shows a limited 
involvement in the barrier itself (Kimelberg et al., 1993).  Regulation of the barrier is a 
complex process which can be dramatically influenced by the neuroimmune system, 
particularly through microglial cytokine secretions. 
 
Innate immunity is known as the “first line of defense” against pathogens and 
constitutes a fast, nonspecific response to pathogen invasion.  Innate mechanisms include 
inflammation, which functions to increase the flow of immune cells to the area as well as 
providing a physical barrier to the spread of pathogens.  This is in contrast to the adaptive 
immune system, which provides a slow, albeit specific response to a pathogen that is 
“remembered” by pathogen-specific t-cells which can mount a fast and powerful response 
in the future.  The brain was originally considered an “immunoprivileged” site due to the 
lack of adaptive immune mechanisms.  It was thought the only interaction between the 
neuroimmune system and the peripheral immune system occurred during the traditional 
neuroinflammatory response due to tissue damage or neurodegenerative disease, defined 
by leukocyte infiltration across the BBB and microglial activation.  Antibodies produced 
by the adaptive immune system, and most cytokines, are too large to passively diffuse 
through the BBB.  However, recent research has demonstrated an active and tightly 
regulated immune system of the CNS that communicates with the peripheral immune 
system through a variety of other mechanisms.   
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Neuroimmune signaling certainly has a traditional role in the neuroinflammatory 
response to pathogens, tissue damage, or a variety of other pathological states.  However, 
recent research has shown that the interaction between the nervous system and the 
neuroimmune system is far more complex than previously imagined.  For example, recent 
evidence has even illuminated the importance of the neuroimmune system in “normal” 
mechanisms, such as neuronal function, signal transduction, plasticity, neuroprotection, 
and neurodevelopment (for a review, see Réaux-Le Goazigo et al., 2013).  Furthermore, 
neuroimmune mechanisms have been shown to influence complex behaviors such as 
“sickness behavior” and alcohol drinking patterns, likely through interactions with 
neurons.  Even the presence of elevated levels of microglia or cytokines does not 
necessarily indicate a neuroinflammatory state because of their role in normal brain 




Microglia are the resident macrophages of the brain and spinal cord (Lawson et al., 
1990) and account for about 15% of the cells found in the brain (Perry, 1998).  Microglia 
are the foundation of the brain’s (innate) immune system and are the only mononuclear 
phagocytic cell in the brain under normal conditions.  Therefore, they provide the first line 
of defense to brain insults and are directly responsible for detecting pathogens and tissue 
damage (e.g. trauma, Streptococcus pneumoniae, etc).  Naturally, they are paramount to 
the initiation of an immune response and can recruit help from peripheral immune cells 
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through the BBB by regulating chemotaxis and endothelial tight junctions (Stamatovic et 
al., 2005; Cushing and Fogelman, 1991; Tieu et al., 2009, Gunn et al., 1997). 
 
The origin of microglia has been debated for decades.  Although it’s possible for 
blood-derived monocytes to cross through the BBB and differentiate into microglia under 
specific circumstances (Lawson et al., 1992), emerging evidence is suggesting that 
embryonic precursors proliferate in the CNS prior to blood hematopoiesis (Ginhoux et al., 
2013).   Additional microglia are observed during inflammation (reactive microgliosis) and 
the source of these is under debate, with a high likelihood of both local proliferation and 
infiltration from the blood (Ginhoux et al., 2013; Capotondo et al., 2012).  In either case, 
they are the only mesoderm-derived cells in the brain.  
 
Microglia undergo stages of activation due to the initiation of activating signals or 
a loss of constitutive inhibitory signaling (such as CX3CR1).  Activators of microglia 
include toxins, dead cells, virus and bacteria constituents, damaged neurons, blood serum 
constituents (BBB leakage), neurotransmitters, and activated astrocytes.  Local cytokines 
can prime or activate microglia, but it is also important to mention that various cytokines 
from the periphery can also prime or activate microglia, including TNFα or MCP-1 (Ferrari 
and Tarelli, 2011).  “Resting” microglia exhibit a ramified morphology which reflects their 
constant scanning of their environment for danger signals.  Activated microglia take on an 
“amoeboid” or “bushy” shape and both migrate and proliferate in response to endogenous 
or exogenous signals (Monk and Shaw, 2006).  Activation of microglia can be fast and 
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long-lasting, and activated microglia increase their expression of characteristic genes.  
However, activated microglia can have several different phenotypes during activation, 
including various neurotrophic or neurotoxic phenotypes (Colton, 2009).  Raivich et al. 
(1999) consider 4 states of microglia activation, each with characteristic morphology and 
cytokine secretions.  “Stage 1” morphology is “alert” or “primed” with thicker but still 
ramified processes and secretions of TGF-B1.  “Stage 2” activation includes 
migratory/proliferating bushy microglia that secrete IL-10.  Both stage 1 and stage 2 are 
mostly neurotrophic and can increase clearance of toxic materials.  Stage 3a and 3b exhibit 
amoeboid morphology and each has characteristic inflammatory cytokine secretions.  
Stage 3a microglia are phagocytic while 3b are mostly bystanders (Raivich et al., 1999).  
Microglia can shift between stages based on environmental stimuli (Kettenmann et al., 
2011).  In chronic neuroinflammation, microglia can stay active for extended periods.  
Experienced microglia could return to a resting state or stay in a primed state, and primed 
microglia “could reveal an altered responsiveness and exert distinct responses upon re-
challenge” (Kettenmann et al., 2011).   
 
Astrocytes also participate in the neuroinflammatory response, including the 
secretion of cytokines, and can, therefore, influence amplification cascades (Block et al., 
2007).  The extent of astrocytic involvement is heavily dependent on microglial factors, 
but is not completely understood (Holm et al, 2012).  Astrocytic responses include 
increasing neuronal excitability (Pascual et al., 2012) and the release of glutamate 
(Jourdain et al., 2007), which could influence neuronal function and/or dysfunction and 
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activate neuroimmune responses.  Microglia can also use cytokine signaling to influence 
astrocytic involvement, including IL-4 to suppress astrocyte function and IL-1 to increase 
astrocyte function (Gehrman et al., 1995).  However, astrocytes seem to be most active 
during the late, recovery stages of inflammatory diseases, rather than initiating 
inflammation (Gehrman et al., 1995).   
 
Microglia can also interact with neurons during both normal and inflammatory 
processes.  Both secrete cytokines, as well as neurotransmitters and both, have receptors 
for cytokines and neurotransmitters (Blalock, 1989).  Neurons are capable of controlling 
the extent of microglial reactivity through direct cell-to-cell interactions, including 
neurotransmitter release as well as cytokine signaling (Carnevale et al., 2007).  This 
includes microglial receptors for noradrenaline, which increases microglial 
proinflammatory cytokine signaling, as well as acetylcholine, which attenuates 
proinflammatory cytokine signaling (Carnevale et al., 2007).  Neurons can also activate 
microglia when damaged, particularly when cell contents are released (e.g. HMGB1).  
HMGB is a common nuclear protein and a powerful endogenous activator of TLR4 
receptors.  HMGB is released when cell membrane integrity is lost, and there is some 
evidence that it can be secreted through NF-kB activation (for a review, see Lotze and 
Tracey, 2005).  Neurons can also produce TNFα and IL-1, which can be used to 
communicate with other neurons as well as microglia (Breder et al., 1988; Breder et al., 
1994).   
 
 11 
Microglia can also communicate with neurons through the release of 
neurotransmitters as well as neuropeptides such as endorphins (for a review, see Domercq 
et al., 2013).  Microglia can also secrete neurotrophic or neurotoxic cytokines depending 
on the context.  Neurotoxic events include the release of prostaglandins, reactive oxygen 
species, proteases, or the removal of neurotrophic factors.  Research is proving that 
microglial neurotoxicity is central to the progression of neurodegenerative disorders.  
Microglial activation or microglial-induced neuroinflammatory processes occur in 
“virtually all brain pathologies” (Ginhoux, 2013) through direct interaction with neurons 
(Perry et al., 2010; Kettenmann et al., 2011; Kingwell, 2012).  For example, microglial 
expression of IL-1 or MCP-1 is associated with neuronal damage in Alzheimer’s disease 
(Mrak and Griffin, 2005; Ishizuka et al., 1997).  Microglial induced neurotoxicity is also 
implicated in Parkinson’s Disease, multiple sclerosis, and most other neurodegenerative 
diseases.  Microglia have also been known to influence neuronal excitability in the CNS or 
PNS, and this excitability has been linked to neuropathic pain (Watkins and Maier, 2002).   
 
Although many cytokines cannot cross the BBB, the CNS is still capable of 
communicating with the peripheral immune system and vice versa.  Peripheral 
inflammation has been known to influence neurotransmitter release in the brain, including 
increasing neuronal firing by 100% in the hypothalamus (Besedovsky et al., 1977).  
Furthermore, brain administration of cytokines or lipopolysaccharide can also activate the 
HPA axis, which then results in the release of glucocorticoids, which can suppress cytokine 
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signaling in the periphery or travel back to the brain and suppress cytokine signaling there 
(Wexler, 1957).   
 
It is important to stress that although communication between microglia and 
neurons or other cells occurs under pathological conditions, microglia also have important 
functions under “normal” conditions as well.  Many of the aforementioned communication 
pathways occur under normal non-inflammatory conditions, although generally to a lesser 
extent.  Evidence shows that microglial functions are critical for neuronal proliferation, 
differentiation, and synaptic formation, pruning, and remodeling (Hughes, 2012; Graeber, 
2010) and respond to neurotransmitters such as glutamate, dopamine, GABA, and purines 
(Graeber, 2010), with acetylcholine having well-known anti-inflammatory properties 
(Borovikova et al., 2000).   
 
NEUROIMMUNE SIGNALING, STRESS, AND BEHAVIOR 
 
The relationship between stress and drug abuse is strong and particularly prevalent 
in the literature.  Evidence is suggesting that neuroimmune signaling may be a mechanism 
through which this relationship is mediated.   
 
To begin, the relationship between neuroimmune signaling and behavior in general 
is very complex and interrelated.  For example, sickness or infection is known to have a 
powerful influence on brain functions and complex behaviors (for a review, see Dantzer et 
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al., 2008).  The presence of cytokine receptors on neurons is one mechanism through which 
sickness-like behaviors are expressed (Tracey, 2009).  For example, the interaction 
between the endogenous danger-signaling molecule HMGB-1 or exogenous 
lipopolysaccharide with the TLR4 receptor can influence neurotransmission and result in 
sickness-like behaviors (Blednov et al., 2011; Okun et al., 2009; Lehnardt, 2010; 
Andersson and Tracey, 2011).  Other cytokines including TNFα and IL-6 are known to 
promote sickness behavior in similar ways.  Another example of neuroimmune systems 
affecting behavior is that intracerebroventricular (ICV) administration of IL-1 is known to 
impair contextual memory in fear conditioning behavior (Barrientos, 2002).   
 
Furthermore, stress and depression are associated with increased levels of cytokines 
in humans and animal models.  This appears to be primarily through cytokine-induced 
dysregulation of the HPA axis as well as dopamine and serotonin systems (Dantzer et al., 
2008).  As previously mentioned, cytokines are known to increase the release of 
corticotropin release hormone (CRH) or cortisol (Hueston & Deak, 2014), which are 
colloquially referred to as stress hormones and can have a dramatic impact on many 
neurotransmitter systems, especially those involved in the regulation of mood.  The 
resulting increase in glucocorticoids can also have a dramatic impact on cytokine signaling 
in the brain or periphery (Munhoz et al., 2006).   
 
The association between stress systems and the neurobiology of addiction is 
particularly strong, especially in the neurobiology of alcohol use disorders.  CRH systems 
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are central in driving addictive-like behaviors through actions in the central extended 
amygdala (CeA), where they act to produce anxiety, anhedonia, compulsive intake of 
drugs, and reinstatement of extinguished drug seeking (For a review, see Zorrila et al., 
2014).  Since stress, mood, and immune function are closely related, particularly in their 
interaction with the HPA axis, neuroimmune mechanisms may be integral in the link 
between stress and drug abuse.     
 
NEUROIMMUNE SIGNALING AND DRUG ABUSE 
 
Evidence is mounting that the neuroimmune system participates in the progressive 
pathological deterioration into drug addiction (for a review, see Crews et al., 2011).  The 
influence of neuroimmune signaling on neurotransmitter activity, HPA axis/endocrine 
function, and CNS development are just a few examples of this link.  Current drug abuse 
models typically distinguish between various stages, including binge/intoxication, 
withdrawal/negative affect, and preoccupation/anticipation or craving (for a review, see 
Mayfield et al., 2013).  Neuroimmune systems (as well as stress systems), have been shown 
to influence all three stages of addiction.  For example, blockade of microglial activation 
prevents conditioned place preference for opioids, stimulants, or alcohol (Narita et al., 
2006; Hutchinson et al., 2008; Agrawal et al., 2011) and reduces, by half, the dopamine 
increases seen by morphine administration (Bland et al., 2009), strong evidence that 
neuroimmune function is involved in the binge/intoxication stage of drug abuse.  
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The negative affect, anhedonia, and reward-deficits seen as a result of the 
administration of innate immune cytokines (or with stress or depression) are akin to the 
behavioral changes seen in drug abuse disorders and are associated with the dysregulation 
of limbic function (Figure 1.1).  Drugs of abuse or restraint stress are known to increase 
the release of cytokines and activate microglia (Blanco and Guerri, 2007; Crews et al., 
2012; Madrigal et al., 2002; Tynan et al., 2010), which, as previously mentioned, contribute 
to dysregulation of the HPA axis as well as dysregulation of dopamine and serotonin 
systems (Dantzer et al., 2008).  Also, glial activation and cytokine release is associated 
with increased excitability of reward pathways (Ren et al., 2012).  Furthermore, mice 
lacking TLR4 receptors are protected against microglial activation, anxiety and cognitive 
impairments seen with chronic alcohol administration (Pascual et al., 2011), drink less 
ethanol than normal mice (Blednov et al., 2012), and have decreased activation of the 
amygdala (Roberto et al., 2008).  LPS administration is also associated with decreased 
firing of dopamine neurons (Blednov et al., 2011).  Furthermore, brain infusions of 
cytokines (including MCP-1) are associated with increased withdrawal-induced anxiety 
(Breese et al., 2011). 
 
Drugs of abuse to are known to cause cognitive impairment, particularly in 
prefrontal function (Schoenbaum and Shaham, 2008), and “neuronal excitability,” both of 
which are associated with increased craving and compulsive drug use.  Neuroimmune 
signaling is associated with both cognitive impairments as well as neuronal excitability.  
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Figure 1.1: Innate immune gene induction creates the neurobiology of addiction. 
Prefrontal control over decision making as well as control over limbic structures is 
compromised due to a hyperglutamatergic state.  Neuroimmune and stress systems interact 
to induce negative affect, craving and anxiety through limbic dysfunction.  Adapted from 




For example, neuroimmune activation is associated with the reduction of seizure thresholds 
in the corticolimbic system (Vezzani et al., 2011; Maroso et al., 2010).  Furthermore, the 
release of glutamate is associated with microglial activation and IL-1 release, and 
neuroimmune signaling increases the phosphorylation of synaptic glutamate receptors 
(Maroso et al., 2010).  The cytokine TNFα increases glutamate neurotoxicity by activating 
NMDA receptors (Zou and Crews, 2005).  Hyperglutamatergic states, which can be 
cytokine-induced, are known to disrupt prefrontal control over limbic systems (Figure 1.1; 
Gruber et al., 2010).  These hyperexcitable states can be associated with craving for drugs 
of abuse (Breese et al., 2011).   A hyperglutamatergic state has been found to increase 
alcohol intake (Spanagel et al., 2005).  Acamprosate, which is FDA-approved for the 
treatment of alcohol use disorders, has been suggested to help cravings by reducing the 
cytokine-induced hyperglutamatergic state.    
 
Furthermore, cognitive impairment may be a result of drug-induced neurotoxicity/ 
neurodegeneration, or a reduction in neurogenesis, all of which have been linked to 
neuroimmune signaling.  For example, drug-induced microglial activation is associated 
with neuronal degeneration in both opioid and methamphetamine use (Raghavendra et al., 
2004; Thomas and Kuhn, 2005).  Furthermore, cytokine release is associated with a 
reduction of neurogenesis (Crews et al., 2011; Zou et al., 2012) and the blockade of NF-
kB prevents against alcohol-induced reduction of neurogenesis (Crews et al., 2006).   
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There is strong evidence that alcohol use disorders are associated with a variety of 
cognitive deficits, including neurodegeneration in corticolimbic system (Crews and Nixon, 
2009; Pfefferbaum et al., 1992; Obernier et al., 2002; Sullivan et al., 1995).  Although this 
is associated with cytokine signaling and microglial activation, it remains unclear which 
comes first, or if the signaling is neurotoxic or neurotrophic (Marshall et al., 2013).  
Furthermore, there is evidence that alcohol-mediated dysregulation of prefrontal NF-kB 
contributes to changes in neuroplasticity seen in drug abuse (Okvist et al., 2007).   
 
Neuroimmune activation may contribute to all three stages of drug abuse through a 
variety of mechanisms.  The interaction between stress, depression, and cytokine signaling 
suggests that neuroimmune signaling is a promising avenue through which to target drug 
abuse therapy. 
 
ALCOHOL AND NEUROIMMUNE SIGNALING 
 
A growing body of literature has implicated neuroimmune signaling, including the 
neuroinflammatory response, in the mechanisms of neurobiological changes that promote 
unhealthy alcohol drinking behavior.  For example, gene expression analyses of alcohol-
preferring rodent strains have revealed candidate genes for high alcohol consumption 
which include many neuroimmune signaling genes (Mulligan et al., 2006; Kimpel et al., 
2007; Tabakoff et al., 2008).  Also, a gene expression study in humans has revealed that 
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the human alcoholic brain has changes in expression related to neuroimmune signaling and 
neurodegeneration when compared to controls (Liu et al., 2006). 
 
Additionally, recent studies have revealed that alcohol can directly affect 
neuroimmune signaling, including an increase in pro-inflammatory signaling.  For 
example, studies have found increases in several cytokines in several regions of the brain 
of mice after intragastric ethanol administration (Qin et al., 2008) or exposure of brain 
slices to ethanol (Zou and Crews, 2010), including MCP-1, TNFα, interleukin-1beta (IL-
1β) proinflammatory proteases TACE and tissue plasminogen activator (tPA), and 
nicotinamide adenine dinucleotide phosphate oxidase (NOX), as well as reductions in anti-
inflammatory cytokine IL-10.  He and Crews (2008) found that ethanol increased cytokine 
levels and increased microglial infiltration in human alcoholic brains.  Other studies have 
shown that ethanol increases inflammatory mediators in a rodent model of adolescent 
ethanol self-administration (Pascual et al., 2007) and a rodent model of chronic ethanol 
exposure (Valles et al., 2004). 
 
These findings have helped fuel the theory that neuroimmune signaling can 
facilitate the development of the alcoholic phenotype and this theory has been supported 
by some recent studies.  A recent study by Blednov et al. (2011) showed that the activation 
of inflammatory signaling with a single systemic injection of lipopolysaccharide produced 
a long-lasting increase in ethanol consumption in a 2-bottle choice paradigm in certain 
strains of mice at various time points after the injection, even up to 80 days after the 
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injection.  Furthermore, the knockout of neuroimmune genes critical for the neuroimmune 
response, including many of the candidate genes from the studies previously mentioned, 
reduced alcohol consumption in animal models, including beta-2-microglobulin (B2m), 
cathepsin S (Ctss), cathepsin F (Ctsf), interleukin 1 receptor antagonist (Il1rn), CD14 
molecule (Cd14), interleukin 6 (Il6), MCP1 (CCL2), CCR2, and CCL3 (Blednov et al., 
2005; Blednov et al, 2011b).  Understanding the role of specific neuroimmune molecules 
in the development of unhealthy drinking behavior would allow for the development of 
targeted neuroimmune modulators for therapeutic use.  
 
MONOCYTE CHEMOATTRACTANT PROTEIN – 1 (MCP-1) 
 
MCP-1 signaling is central to the neuroinflammatory response, with its main 
functions being to recruit microglia to sites of brain injury and, at higher concentrations, to 
regulate blood-brain barrier permeability and leukocyte infiltration (Piao et al., 2008; 
Stamatovic et al., 2005; Gunn et al., 1997).  MCP-1 has been implicated in a variety of 
neuroinflammatory and neurodegenerative diseases, including brain ischemia, multiple 
sclerosis, traumatic brain injury, Alzheimer’s Disease, and experimental autoimmune 
encephalomyelitis (Conductier et al., 2010).   
 
In addition to providing the most potent chemotactic gradient (Sozzani et al., 1994), 
MCP-1 binds to its innate receptor (CCR2) on neurons, astrocytes, and activated microglia 
(Banisadr et al., 2002), endothelial cells (Stamatovic et al., 2005) and infiltrating 
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leukocytes (Cushing and Fogelman, 1991), to induce neuroimmune gene expression and a 
variety of cellular responses.  In activated microglia, this results in the activation of the 
transcription factor nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB), 
resulting in cellular motility and the induction of neuroimmune signaling genes (Figure 
1.2; Piao et al., 2008).  Astrocytes, neurons, infiltrating leukocytes, and activated microglia 
can also secrete MCP-1 in response to a variety of stimuli (for a review, see Semple et al., 
2010).  However, MCP-1 by itself cannot activate microglia, and microglia do not secrete 
MCP-1 until activated (Hinojosa et al., 2011; Flugel et al., 2001; Gourmala et al., 1997; 
Gunn et al., 1997). 
 
The presence of CCR2 receptors on neurons is fitting given the role that neurons 
play in the neuroinflammatory responses as well as sickness behavior.  MCP-1 receptors 
(CCR2) are found throughout the brain and are particularly dense in the prefrontal cortex, 
nucleus accumbens, amygdala, and ventral tegmental area, and include neuronal expression 
in many of these areas (Banisadr et al., 2002; Banisadr et al., 2005).  MCP-1 is also secreted 
from many of those same brain regions as well (Banisadr et al., 2005b).  Many of these 
brain regions are noteworthy because they are known to have a role in behavioral 
pathology, including drug abuse and addiction.  The activation of CCR2 on GABA neurons 
has an allosteric inhibitory effect, where administration of MCP-1 alone has no effect on 
firing patterns, but causes a dose-dependent decrease in GABA-induced inward currents 
(Gosselin et al., 2005).  Spinal cord neurons bathed in 10nm MCP-1 had a 50% reduction  
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Figure 1.2: Overview of the intracellular cascade activated by CCR2. 
All chemokine receptors are g-protein coupled receptors.  CCR2 receptor activation results 
in the activation of protein kinase C, which in microglia, activates the transcription factor 
NF-kB.  CCR2 activation in microglia results in the downstream effects of cellular mobility 




in current due to 100uM GABA, while 100nM MCP-1 nearly eliminated the current 
(Gosselin et al., 2005).  Again, this could be particularly meaningful for interactions with 
drugs of abuse, especially those that act on GABA receptors, such as alcohol.  Furthermore, 
MCP-1 receptors are located on dopamine neurons in the basal ganglia, which have a well-
documented effect on motivated behaviors (Salamone and Correa 2002).  CCR2 receptors 
are constitutively expressed on dopamine neurons (Banisadr et al., 2005), the activation of 
which leads to increases in phosphorylated tyrosine hydroxylase (Wakida et al., 2014) and 
increases in dopamine release (Guyon et al., 2009).  There is some evidence that this is due 
to MCP-1 modulation of potassium channels (Guyon et al, 2009; Apartis et al, 2010; 
Wakida et al., 2014).  However, it’s also possible that MCP-1 leads to an increase in 
dopamine release through a well-known interaction between GABAergic interneurons and 
dopamine neurons in the VTA, where decreases in GABA release result in increases in 
dopamine release (Valenta et al., 2013).  Others have shown that CRF can increase the 
presence of CCR2 on dopamine neurons, possibly through an interaction with TLR4 (June 
et al., 2015).  Altogether, these data suggest that MCP-1 can influence motivation, reward, 
and anhedonia through modulation of neuronal activity, particularly through actions on 
neurons. 
 
MCP-1 AND ALCOHOL 
 
One cytokine in particular, monocyte chemoattractant protein 1 (MCP-1 or CCL2) 
and its receptor, CCR2, are of particular interest.  There is evidence that MCP-1 promotes 
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ethanol-induced neurobiological changes. For example, brain injections of MCP-1 
progressively exaggerate alcohol withdrawal-induced anxiety behavior (Breese et al., 
2008). Also, there is evidence that alcohol directly increases MCP-1 signaling. Zou and 
Crews (2010) discovered a 1000% increase in MCP-1 over control animals in brain slices 
exposed to alcohol, MCP-1 concentrations were increased by 2-3 fold in a mice after 
intragastric administration of 5 g/kg ethanol for 8 days (Qin et al., 2008), and MCP-1 levels 
were increased by 2 to 3-fold in several regions of human alcoholic brains compared to 
controls (He and Crews, 2008). Furthermore, there is evidence that MCP-1 signaling 
modulates alcohol drinking behavior. MCP-1 receptor (CCR2) knockout mice had a robust 
reduction in alcohol consumption and a reduced preference for alcohol (Figure 1.3; 




Altogether, this data suggests that MCP-1 signaling is important in the development 
of ethanol drinking behavior of wild-type rodents, that MCP-1 signaling may accelerate 
the onset of alcohol dependence or increase the severity of alcohol dependence, and 
identifies MCP-1 and its receptor as potential target molecules for therapeutic intervention.  
The goal of my dissertation is to test the hypothesis that MCP-1-mediated neuroimmune 
signaling can influence alcohol self-administration.  In particular, we theorize that 
enhancing MCP-1 signaling will accelerate the onset of drinking behavior and increase the 
severity of drinking behavior.  Generally speaking, I accomplished this by   
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Figure 1.3: MCP-1 and CCR2 knockout mice drink less ethanol. 
Escalating concentrations of ethanol were offered for 4 days at a time using a home-cage, 
2 bottle choice design.  In the left panel, wild type mice (C57BL/6J) are compared to CCL2 
knockout mice and CCL3 knockout mice.  ANOVA for wild type vs CCL2 knockout was 
not significant, but post-hoc analysis revealed a significance at 15% ethanol.  In the right 
panel, double CCR2/CCL2 KO mice drank significantly less than either KO individually.  
The double-KO compared to wild-type in the left panel demonstrates the power of MCP-1 





increasing the amount of MCP-1 signaling in the brain and then measured drinking 
behavior. There are three phases of drinking behavior I investigated. First, I looked at the 
acquisition of drinking behavior (i.e. an animal that has never drunk before was given a 
chronic infusion of MCP-1 and I measured how fast the animal began to drink and how 
fast the drinking escalated).  After a week or so, the animals generally stabilized their 
alcohol intake, and I measured if the MCP-1 infusion influenced the average daily intake 
during “stable” intake for several weeks.  Third, I looked at how long the influence on 




Chapter 2: Methods Overview 
 
In order to keep the accepted manuscript with the MCP-1 experiments in an 
unmodified form (Chapter 3), I have included this chapter to describe methodology details 
that were not included in the manuscript. 
 
MICROINJECTION OF MCP-1 
 
MCP-1 signaling is complex and can lead to a variety of behavioral changes in the 
animal over time.  There seem to be two distinct MCP-1 mediated effects on behavior after 
central administration; the acute transient depressive effects (Banisadr et al., 2002; Plata-
Salaman and Borkoski, 1994) and the sustained behavioral effects (Breese et al., 2008).  
The study by Banisadr et al., (2002) found a decrease in locomotor activity 4 minutes after 
the MCP-1 injection, while Breese et al., (2008) tested locomotor activity several days 
later, after 5 days of ethanol administration, and found no effect.  Loss of appetite was 
found 2 hours after microinjection but recovered by 24 hours (Plata-Salaman and Borkoski, 
1994).  Persistent effects include hyperalgesia and allodynia, which can last for 2-4 days 
(Baamonde et al., 2011; Tanaka et al., 2004; Dansereau et al., 2008), as well as chronic 
elevation in withdrawal-induced anxiety, measured 1-2 weeks later (Breese et al., 2008), 
and leukocyte infiltration, measured several days later (Stamatovic et al., 2005).  Therefore, 
the timing of the delivery of MCP-1 are critical in regards to making accurate and 
meaningful measurements of their effect on operant self-administration.   Furthermore, the 
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chronic nature of the experiment would require many stressful microinjections over several 
weeks, inviting another confounding variable and the likelihood that many rodents would 
be lost.  Therefore, we plan to use an osmotic minipump, which will allow us to 
continuously perfuse very low volumes over extended amounts of time, with certain 
models of the Azlet® osmotic minipump capable of delivering 0.1 microliters per hour 
over 5 weeks.  These pumps have been previously used to successfully administer chronic 
ICV MCP-1 (Stamatovic et al., 2005).   
 
The ICV technique has been chosen due to the limited ability of MCP-1 to cross 
the blood brain barrier.  ICV microinjections of cytokines, including MCP-1, and their 
antagonists have been shown to distribute into the brain parenchyma (Proeschold et al., 
2002; Callewaere et al., 2006; Stamatovic et al., 2005).  Unilateral ICV microinjections of 
cytokines induce brain-wide effects including glial activation and immune cell infiltration 
(Proeschold et al., 2002), and unilateral intracranial or ICV microinjections of MCP-1 
using the osmotic minipump cause robust brain-wide effects including leukocyte 
infiltration (Stamatovic et al., 2005).  Therefore, we plan to implant only one cannula and 
one osmotic minipump.  Continuous delivery of MCP-1 or vehicle (ACSF) will continue 
while the animal recovers.  Following the technique of Banisadr et al., (2002), the 
stereotaxic coordinates from Paxinos and Watson (1998) will be AP: – 0.9 mm, ML: 1.5 
mm from bregma, DV: 2.5 mm from the skull surface.  
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The doses of MCP-1 were chosen based on its ability to stimulate persistent 
behavioral effects while not stimulating leukocyte infiltration or breakdown of the blood-
brain barrier (Stamatovic et al., 2005).  A dose of 20 ng to 100 ng of ICV MCP-1, 
administered as a bolus, has been used effectively by many researchers (Plata-Salaman and 
Borkoski, 1994; Banisadr et al., 2002; Breese et al., 2008; Baamonde et al., 2011; Tanaka 
et al., 2004; Dansereau et al., 2008).  However, due to the difficulty in translating a bolus 
dose into a chronic infusion rate, we made sure to use a wide range of doses.  Therefore, 
we will start with an osmotic delivery rate of 20 ng of MCP-1 per 24 hours and also include 
100-fold higher and 100-fold lower doses.  The threshold of blood-brain-barrier breakdown 




Surgery will be planned so that animals will have a minimum of 4 days to recover 
before operant sessions begin.  All instruments and materials are sterilized prior to use. 
Aseptic technique is used throughout the procedure. Anesthesia is carried out using 
isoflurane gas. Induction is at 5% and maintenance is at 2-3% (2 liter/min in O2).  After 
induction, the surgery site (top of animal's head) is shaved.  Pre-incision, the surgery site 
is rough scrubbed with 10% povidone-iodine.  The animal is secured in a stereotaxic 
apparatus using ear bars and a tooth hook to properly align the head for the stereotaxic 
surgery. A cut is made (approximately 1 inch long) on top of the skull.  The skull is cleaned 
to expose surface landmarks.  A small hole is drilled into the skull at the appropriate 
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position, based on anatomic coordinates, to place a stainless steel guide cannula above the 
desired structure.  The cannula will be used as a chronic microinfusion tube, connected to 
an osmotic minipump (www.alzet.com) that will be implanted under the skin of the upper 
back.  The minipump (approximate volume 200uL) will be pushed under the skin from the 
head to the upper back, so no additional cuts will be made.  The pumps, cannula and tubing 
connecting the two arrive sterile but are safe to be re-sterilized through one of several 
procedures if necessary.  No tether bolt, screws, or dental cement are necessary to install 
the guide cannula, only a small drop of super glue.  This will allow for a quick surgery 
(<1hr) and leave a small wound and should facilitate healing.  Sutures or staples are placed 
along the incisions as needed for proper healing. Bupivicaine will be administered 
intradermally and topically around the wound sites. Gentamicin and Neosporin ointment 
are applied topically, immediately and any time afterward for wound care.   
 
Recovery is monitored continuously within the surgery suite until the animal is 
conscious.  Water, soft baby cereal, and pellets are provided in the cage.  The soft cereal is 
removed the following day.  Body weight is monitored daily for 3-5 days after surgery, in 
addition to any day of testing.  Our previous experience with this technique suggests the 
procedure is well tolerated by the animals.  Any new wounds or worsening wounds will be 
reported to the vet staff and subsequent wound care will be determined by the veterinary 
staff.  The rat will be monitored and if the microinjector becomes loose, the rodent will be 
euthanized.  Additionally, lack of gain of body weight after surgery, lack of normal 
grooming and locomotion, redness or discharge around eyes, lack of eating or drinking 
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would indicate that the rat is not recovering normally and the rat will be promptly 
euthanized.   
 
JUSTIFICATION FOR THE USE OF LONG-EVANS RATS 
 
The use of whole animals (rats) is required for these studies because some of the 
mechanisms of ethanol are due to interactions between neurons and brain regions which 
will only be operative in the whole animal. Rats exhibit most of the pharmacological effects 
of ethanol, including self-administration, intoxication, persistence of ethanol-seeking, and, 
therefore, represent a useful model of human drinking. The interactions we are studying 
cannot be modeled using tissue culture or invertebrates. The size of the brain also allows 
precise placement of microinjectors and probes to investigate specific brain regions that 
may contribute to the mechanisms that we study. A smaller species such as a mouse would 
make precise placements very difficult.  We do not need to use larger animals because we 
have been able to achieve good results with rats. We do not yet have a clear understanding 
of the molecular and cellular effects of ethanol on brain function to generate a computer 
model. Human epidemiological studies cannot be used to understand the effects of changes 
in neurochemistry produced by ethanol consumption. 
 
Male Long-Evans rodents (Rattus norvegicus) were used in all experiments since 
they display reliable ethanol self-administration at intoxicating levels using the models 
proposed.   A priori power analysis determined that to observe an effect size of 20%, with 
 32 
power set at 0.80, we will need a minimum of 10 animals per group. We chose 12 per group 
because we expect some attrition due to incorrect probe placements or rats that do not drink 
enough alcohol to be used for the experiment. Lower numbers of animals will give a high 
probability of coming to a false conclusion regarding the results  
 
The Animal Resources Center maintains a full-time staff for the care of the animals. 
Drs. Glen Otto and Kathleen Roellich are the University’s full-time veterinarians. They are 
both available 24 hours a day for help with animal care, and they routinely participate in 
the training of investigators. Our lab also personally monitors animals daily for health. We 
very closely monitor the recovery of animals that have had surgery. If we encounter any 
problems, we contact Drs. Otto or Roellich who advise us on the best course of action.   
 
All procedures will be carried out in strict accordance to the NIH Guide for the Care 
and Use of Laboratory Animals and will be approved by the Institutional Animal Care and 
Use Committee of the University of Texas at Austin. The Animal Resources Center at the 
University of Texas at Austin is AAALAC certified and has a full-time animal care staff 
and 24-hour veterinary care. The neurochemical measurements which are proposed are 
especially susceptible to stress in the animals and because of this and ethical 
considerations, stress will be minimized. Rodents will be monitored several times a day by 
animal care staff as well as me and the researchers helping me. All personnel have been 
trained in general animal and experimental guidelines through coursework provided by the 
American Association for Laboratory Animal Science (AALAS), including “Rodent 
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Handling Techniques” and “Pain Recognition and Alleviation.”  Any signs of distress will 
be immediately reported to the veterinary staff and proper action taken. All surgeries will 
be performed with proper anesthesia and animals will be monitored constantly. 
 
IACUC approved standard protocols, and NIH and AVMA guidelines for 
euthanasia will be followed. After operant testing is complete, animals will be sacrificed 
using Euthasol ® solution (pentobarbital 150mg/kg). This method has been chosen because 
it causes no distress to the animal other than the minimal transient pain of intraperitoneal 
injection. However, under most circumstances, the animal will be injected with Euthasol 




Chapter 3: Chronic intracerebroventricular infusion of monocyte 
chemoattractant protein – 1 leads to a persistent increase in sweetened 
ethanol consumption during operant self-administration but does not 
influence sucrose consumption in Long-Evans rats. 
 
This work was accepted for publication in Alcoholism: Clinical and Experimental 
Research on October 12, 2015, under the same title, by Valenta JP and Gonzales RA.  It is 




Background:  Among the evidence implicating neuroimmune signaling in alcohol use 
disorders are increased levels of the chemokine monocyte chemoattractant protein-1 
(MCP-1) in the brains of human alcoholics and animal models of alcohol abuse.  However, 
it is not known whether neuroimmune signaling can directly increase ethanol consumption, 
and whether MCP-1 is involved in that mechanism.  We designed experiments to determine 
if MCP-1 signaling itself is sufficient to accelerate or increase ethanol consumption.  Our 
hypothesis was that increasing MCP-1 signaling by directly infusing it into the brain would 
increase operant ethanol self-administration. 
Methods:  We implanted osmotic minipumps to chronically infuse either one of several 
doses of MCP-1 or vehicle into the cerebral ventricles (ICV) of Long-Evans rats and then 
tested them in the operant self-administration of a sweetened ethanol solution for 8 weeks. 
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Results:  There was a significant interaction between dose of MCP-1 and sweetened 
ethanol consumed across the first 4 weeks (while pumps were flowing) and across the 8-
week experiment. Animals receiving the highest dose of MCP-1 (2 µg/day) were the 
highest consumers of ethanol during weeks 3 through 8.  MCP-1 did not influence the 
acquisition of self-administration (measured across the first 5 days), the motivation to 
consume ethanol (time to lever press or progressive ratio), withdrawal-induced anxiety, or 
the consumption of sucrose alone. 
Conclusion:  We provide novel evidence that neuroimmune signaling can directly increase 
chronic operant ethanol self-administration, and that this increase persists beyond the 
administration of the cytokine.  These data suggest that ethanol-induced increases in MCP-
1, or increases in MCP-1 due to various other neuroimmune mechanisms, may further 
promote ethanol consumption.  Continued research into this mechanism, particularly using 
models of alcohol dependence, will help determine if targeting MCP-1 signaling has 
therapeutic potential in the treatment of alcohol use disorders.   





Recent research has implicated neuroimmune signaling in the neurobiological 
changes that promote unhealthy alcohol drinking behavior (for a review, see Crews et al., 
2011).  A variety of experiments have revealed that a specific chemokine, monocyte 
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chemoattractant protein-1 (MCP-1, or CCL2), and its receptor, CCR2, are particularly 
significant.  For example, Zou and Crews (2010) discovered a 1000% increase in MCP-1 
in brain slice cultures treated with ethanol, relative to controls.  Brain MCP-1 
concentrations were increased 2-3 fold in mouse models of sub-chronic or chronic ethanol 
exposure (Qin et al. 2008, Pascual et al., 2015), in a rat model of chronic ethanol exposure 
(Ehrlich et al., 2012), as well as in human alcoholic brains post-mortem (He and Crews, 
2008).  Ehrlich and colleagues (2012) found elevated cortical MCP-1 in rats on a 20% 
ethanol liquid-only diet for 12 months.  Furthermore, manipulating MCP-1 signaling can 
influence ethanol self-administration in animal models.  For example, MCP-1 ligand, 
receptor, and combined ligand and receptor knockout mice had a robust reduction in 
ethanol consumption and preference (Blednov et al., 2005).  More recently, siRNA-
mediated knockdown of neuronal MCP-1 expression in the ventral tegmental area or 
central amygdala resulted in marked decreases in operant responding for ethanol (June et 
al., 2015).  Additionally, June et al. (2015) found evidence that corticotropin-releasing 
factor (CRF) modulates MCP-1 expression in neurons.  Interestingly, MCP-1 has been 
previously shown to enhance dopamine neurotransmission through modulation of 
potassium channels (Guyon et al, 2009; Apartis et al, 2010; Wakida et al., 2014), leading 
the authors of June et al. (2015) to hypothesize that CRF signaling regulates excessive 
alcohol drinking through the modulation of MCP-1 expression on dopamine neurons.  
Altogether, these data suggest that ethanol-induced increases in MCP-1 may facilitate 
increased ethanol consumption.  Experimental manipulation to determine if MCP-1 
signaling itself can directly increase ethanol consumption was warranted. 
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Our hypothesis was that increasing MCP-1 signaling by directly infusing it into the 
brain would increase the operant self-administration of sweetened ethanol.  We designed 
an experiment that would allow us to independently examine the effect of MCP-1 on 
several distinct components of ethanol self-administration, including acquisition, 
motivation, and consumption.   We also examined withdrawal-induced anxiety.  We 
implanted subcutaneous osmotic minipumps connected to intracranial cannulae to 
chronically infuse a wide range of concentrations of MCP-1 into the cerebral ventricles 
(ICV) of Long-Evans rats, using doses that are substantially below those required to trigger 
neuroinflammatory mechanisms such as BBB breakdown or leukocyte infiltration 
(Stamatovic et al., 2005).  We provide novel evidence that neuroimmune signaling can 
directly increase chronic operant ethanol self-administration, and that this increase persists 
beyond the administration of the cytokine. 
 




During the 1st week, animals were acclimated and handled.  During the 2nd week, 
animals were trained to lever press.  During the 3rd week, MCP-1 was reconstituted and 
osmotic minipumps were filled and surgically implanted for ICV delivery of MCP-1.  
During weeks 4 through 11 (8 weeks), animals performed daily operant self-administration 
sessions of a sucrose-sweetened ethanol solution (Monday-Friday).  Pumps delivered 
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MCP-1 continuously for 5 weeks and self-administration started during the 2nd week of 
delivery.  Progressive ratio and withdrawal-induced anxiety tests were performed on the 
Sunday at the end of the 4th week of self-administration (on the last day of pump delivery 
of MCP-1).  The self-administration of a sucrose solution without ethanol was performed 
in a separate group of animals and followed this timeline except that the experiment was 




We used male Long-Evans rats (Charles River Laboratories, Wilmington, MA) 
weighing an average of 190 grams upon arrival and 350 grams on the first day of ethanol 
self-administration.  The rats were dual-housed at 25 °C on a 12-h light/dark schedule 
(lights on 7 am to 7 pm) with ad libitum access to food and water in an AAALAC-
accredited facility. All procedures were carried out in compliance with the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved 
by the Institutional Animal Care and Use Committee of the University of Texas at Austin. 
Care was given to minimize stress to the animals.  Animals were dual-housed 
immediately upon arrival and throughout the experiment.  Rats were handled by every 
experimenter for at least 4 days prior to operant training for a total of 15-20 minutes each 
day.  Each cage had a nylabone for enrichment throughout the study.  Bedding was made 
from wood chips and was replaced weekly.  The animal housing room is only occupied by 
rats used by the Gonzales lab and is adjacent to the room with operant chambers.  Animals 
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are carried from their home cage through one open door directly to the operant chambers.  
Operant chambers are cleaned daily.  The two rooms are isolated from other traffic and 




Animals were water deprived for 16-22 hours per day and trained to lever press for 
a 10% sucrose solution using an FR1 schedule of reinforcement.  Self-administration took 
place in standard operant chambers (Med Associates Inc., St. Albans, VT). Each chamber 
contained a single, retractable lever on the left side (2 cm above the grid floor).   Each time 
the animal pressed the lever, a retractable drinking spout entered the chamber on the right 
side of the same wall (5 cm above the grid floor). An interior chamber light and a sound-
attenuating fan were activated with the start of each operant session. Operant chamber 
components were controlled by a personal computer running MEDPC software (Med 
Associates Inc., St. Albans, VT).  Initially, 1-hour sessions were used, with session duration 
declining to 40 minutes and then 20 minutes for individual animals as they made progress.  
All rats were trained to lever press successfully within 5 days, with 20-minute sessions 







Recombinant rat MCP-1 (Peprotech, Rocky Hill, NJ) was dissolved in dH2O and 
then diluted in concentrated artificial cerebro-spinal fluid (aCSF) to reach a standard final 
concentration of 149 mM NaCl, 2.8 mM KCl, 1.2 mM MgCl2,1.2 mM CaCl2, 0.42 mM 
ascorbic acid, 5.4 mM D-glucose, and 1% rat serum albumin (Sigma-Aldrich, St. Louis, 
MO).  The solution was then serially diluted in aCSF (with final salt and albumin 
concentrations) to reach desired MCP-1 concentrations.  Alzet osmotic minipumps (model 
1004) and brain infusion cannulae (“kit 2”, 28 ga) were obtained from Durect Corporation 
(Cupertino, CA).  Pumps were filled with a specific concentration of MCP-1 adjusted to 
each lot’s individual fill volume and flow rate to yield a final dose of either 0.2 ng/day, 20 
ng/day, 2000 ng/day, or vehicle control.  An additional group of 2 ng/day pumps were used 
for the ELISA experiment.  The osmotic pumps used were designed to flow at a constant 
rate of 0.12 µL/hr for 34.5-35.9 days with a mean fill volume of approximately 100 µL, 
leading to an MCP-1 concentration of approximately 54 µM for the 2000 ng/day dose.  
MCP-1 was reconstituted and pumps were filled on Mondays and primed in sterile saline 
at 37°C to ensure reliable flow prior to implantation (which occurred on Tuesdays and 
Wednesdays), and should have reliably stopped flowing on the 35th day, according to the 
manufacturer. 
The dose of MCP-1 was chosen based on the ability of an acute ICV dose of 20 – 
100 ng to induce persistent behavioral effects (Plata-Salaman and Borkoski, 1994; 
Banisadr et al., 2002; Breese et al., 2008).  Based on those experiments, we centered on the 
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delivery of 20 ng over a 24-hour period and then included 100-fold higher and 100-fold 
lower doses (which do not compromise the blood-brain barrier or lead to leukocyte 
infiltration when administered ICV (see discussion)).  The chronic infusion method was 
chosen due to the propensity of the interaction between ethanol and neuroimmune signaling 
to be chronic in nature.  We chose the ICV method to simulate the presence of brain-
induced MCP-1 and the method’s ability to target the whole brain with molecules that don’t 
readily cross the blood-brain barrier (Dzenko et al., 2001).  Evidence shows that ICV 
administration of MCP-1 or other cytokines distributes throughout the brain to initiate 




The cannula tip was aimed at the left lateral ventricle using the following 
coordinates relative to bregma (mm): anterior/posterior -0.60, medial/lateral +1.50, and 
dorsal/ventral -3.80, and was then glued to the skull using cyanoacrylate adhesive.  The 
pump was implanted subcutaneously in a pocket just under the skin which was created by 
sliding needle holders through a head incision to the mid upper-back region.  A 5 cm 
polyethylene tube connected the pump to the L-shaped cannula.  The skin was sutured over 
the cannula once the tab for stereotaxic placement was removed.  Bupivicaine (Hospira, 
Inc., Lake Forest, IL) was administered intradermally, and both bupivacaine and 
gentamicin (APP Pharmaceuticals, LLC, Schaumburg, IL) were dripped into the wound (2 




Animals drank either a solution of 10% sucrose (w/v) alone or a solution with both 
10% sucrose (w/v) and 10% ethanol (v/v).  The solutions were made using 95 % ethanol 
(Aaper Alcohol and Chemical Co., Shelbyville, KY) and molecular biology grade D-
sucrose (Fisher, Hampton, New Hampshire) dissolved in tap water.   
Animals began self-administration the week after surgery (5-6 days after 
implantation).  Animals self-administered Monday through Friday for 8 weeks, of which 
pumps delivered MPC-1 during the first 4 weeks.  Self-administration sessions occurred 
between 5 and 8 hours into the light cycle.  Due to the presence of sucrose, intake levels 
stabilize within a few days.  We defined acquisition as the intake values across the first 5 
days.  The self-administration of 10% sucrose without ethanol was measured in a distinct 
group of animals and followed these methods, except limited to just the first 4 weeks of 
self-administration and the highest dose of MCP-1 (2000 ng/day) and controls. 
To capture whether MCP-1 influenced the motivation to gain access to ethanol 
independent of the quantity consumed, we chose an appetitive-consummatory model of 
self-administration.  The appetitive phase required the animal to press a lever 4 times in 
order to gain access to the ethanol solution, and the time taken to reach this response 
requirement was recorded.  This phase was followed by the consummatory phase, which 
consisted of 20 minutes of access to the ethanol solution, and the amount of ethanol 
consumed was recorded.  If 20 minutes passed without the animal pressing 4 times, access 
to the ethanol was automatically given.  Ethanol was contained in a retractable sipper tube 
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with a 50 mL conical vial.  Drippage was collected in a weigh boat, and both the vial/tube 
and the dish were weighed before and after the session to the hundredths of an mL.  
As a secondary test of motivation, a progressive ratio test was administered on the 
final day of pump flow (the Sunday of the 5th week).  We followed the model of Walker 
and Koob (2007) and used the following schedule of reinforcement: 
2,2,3,3,4,4,5,5,7,7,9,9,11,11,13,13,15,15,18,18.  The amount of ethanol consumed and the 
break point reached were measured.   
Since MCP-1 is an inflammatory molecule with unknown effects during chronic 
administration, animals were closely monitored for illness, including body weight and 
locomotor activity.  Locomotor activity was only recorded during the 20 minutes of ethanol 




Six to 8 hours after the progressive ratio session, animals were tested for 
withdrawal-induced anxiety by measuring the seconds of social interaction they initiated 
with an unfamiliar animal with a matched dose of MCP-1 over a 5 minute period.  
Generally, interaction was defined as contact directed at the other animal (sniffing, 
grooming, crawling, fighting, etc) and took place in a square open field (60 x 60 cm2, with 
16 squares marked on the floor for assessing locomotor activity) and under low-lighting.  
A minimum of two observers, each blind to the treatment conditions, independently scored 
social interaction and locomotor activity.   
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Enzyme-Linked Immunosorbent Assay (ELISA) 
 
The stability of MCP-1 under the experimental conditions was unknown.  In a 
separate experiment, rat MCP-1 ELISA kits (Life Technologies, Grand Island, NY) were 
used to determine the stability of MCP-1 across the infusion duration.  We tested the 
concentration of MCP-1 in the pumps of animals 14 and 28 days after MCP-1 was 
reconstituted and then diluted to a 2 ng/day dose (after 1 and 3 weeks of drinking, 
respectively).  Pumps were taken from drinking animals that were sacrificed at the day of 





After the experiment, animals were sacrificed using CO2 and then decapitated.  
Brains were extracted and put into 10% formalin for 3 days before being sliced and 
immediately examined under a microscope to determine cannula placement using Paxinos 




Daily values were averaged for each week for each animal.  A repeated measures 
ANOVA with a type I error set to P<0.05 was conducted across 4-week and 8-week data 
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sets (the first four weeks while pumps were flowing, the last four weeks while pumps were 
stopped, and the eight week combined set), or the first 5 days for the acquisition analysis.  
A one-way ANOVA was used for one-time experiments (progressive ratio and anxiety).  




MCP-1 did not increase the operant self-administration of sucrose alone. 
 
Chronic ICV infusion of MCP-1 started 1 week before the initiation of self-
administration and continued for 4 weeks of self-administration, for a total of 5 weeks of 
infusion.  MCP-1 did not significantly influence the self-administration of 10% sucrose 
solution (Figure 2.1, F3,39=0.04, P=0.99, dose x time interaction, n=7 for controls and n=8 
for MCP-1 group).  Only the highest dose of MCP-1 (2000 ng/day) was tested. 
 
MCP-1 did not influence the acquisition of operant self-administration of sweetened 
ethanol. 
 
Chronic ICV infusion of MCP-1 started 1 week before the initiation of self-
administration and continued through the acquisition period (5 days).  ICV infusion of   
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Figure 2.1: The effect of MCP-1 on the self-administration of sucrose. 
MCP-1 was administered using subcutaneous osmotic minipumps over 5 weeks (1 week 
of recovery followed by 4 weeks of self-administration with pumps flowing) followed by 
4 weeks of self-administration without flow.  MCP-1 did not influence the self-




MCP-1 had no effect on the acquisition of operant self-administration of sweetened 
ethanol, measured during the first 5 days (Figure 2.2, F12,156=1.40, P=0.17 dose x time 
interaction, N=11/10/11/11 for control/0.2/20/2000 ng/day doses respectively).   
 
MCP-1 increased consumption during chronic operant self-administration of 
sweetened ethanol.  
 
Chronic ICV infusion of MCP-1 started 1 week before the initiation of self-
administration and continued during 4 weeks of self-administration, for a total of 5 weeks 
of infusion.  Self-administration took place across 8 weeks, the first 4 of which MCP-1 was 
being delivered.  MCP-1 increased the self-administration of sweetened ethanol over 8 
weeks with animals receiving the highest dose of MCP-1 (2 µg/day) drinking the most 
ethanol on average during weeks 3 through 8 (Figure 2.3/2.4, F21,168 =1.65, P=0.04), dose 
x time interaction, n=7/6/7/8 for control/0.2/20/2000 ng/day doses respectively).  The 
effect was also significant for the first 4 weeks of self-administration alone, while the 
pumps were flowing (F9,72 =2.33, P=0.02, dose x time interaction).  The effect was not 
significant when analyzed over the final 4-week period (F9,72=1.566, P=0.14, dose x time 
interaction).  Of the 43 animals used for the acquisition experiment, 28 were used for the 
chronic self-administration analyses (12 animals had pumps that stopped prior to 4 weeks, 





Figure 2.2: The effect of MCP-1 on the acquisition of ethanol intake. 
ICV infusion of MCP-1 had no effect on the first 5 days of operant self-administration of 
sweetened ethanol (P=0.17, N=11/10/11/11 for control/0.2/20/2000 ng/day doses 






Figure 2.3: The effect of MCP-1 on the self-administration of sweetened ethanol. 
MCP-1 increased the self-administration of sweetened ethanol over 8 weeks (P=0.04, 
n=7/6/7/8 for control/0.2/20/2000 ng/day doses respectively).  The data is split across 2 
graphs for clarity.  The effect was also significant for the first four weeks of self-
administration alone, while pumps were flowing (P=0.02).  MCP-1 did not influence 
drinking over the final four-week period (P=0.14).  For clarity, not all error bars are 
included.  The black bar indicates MCP-1 infusion, which began one week prior to the 




Figure 2.4: The effect of MCP-1 on the self-administration of sweetened ethanol. 
MCP-1 increased the self-administration of sweetened ethanol over 8 weeks (P=0.04, 
n=7/6/7/8 for control/0.2/20/2000 ng/day doses respectively).  The data is split across 2 
graphs for clarity.  The effect was also significant for the first four weeks of self-
administration alone, while pumps were flowing (P=0.02).  MCP-1 did not influence 
drinking over the final four-week period (P=0.14).  For clarity, not all error bars are 
included.  The black bar indicates MCP-1 infusion, which began one week prior to the 
initiation of self-administration.   
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MCP-1 did not influence health-related measures. 
 
MCP-1 had no effect on the body weight of the animals (F9,72=0.85, P=0.58, dose 
x time interaction, n=7/6/7/8 for control/0.2/20/2000 ng/day doses respectively) or 
locomotor activity (F9,60=0.85, P=0.58, dose x time interaction, n=6/5/6/7 for 
control/0.2/20/2000 ng/day doses respectively) across the first 4 weeks of drinking.  A 
summary of the data averaged across the first 4 weeks of drinking is shown in Figure 2.5 
and Figure 2.6 for the body weight and locomotor activity, respectively.  There was also 
no effect on % baseline body weight or any of the 8-week analyses (data not shown).  No 
other overt signs of sickness were detected throughout the experiments.   
 
MCP-1 did not increase the motivation to consume sweetened ethanol. 
 
There was no effect on the time to reach the response requirement of 4 lever presses 
to gain access to the ethanol solution across the four weeks of drinking (F9,72=0.49, P=0.88, 
dose x time interaction, n=7/6/7/8 for control/0.2/20/2000 ng/day doses respectively).  A 
summary of the data averaged across the first 4 weeks of drinking is shown in Figure 2.7.  
There was also no effect across 8 weeks (data not shown).  Animals that took longer than 
2 standard deviations from the mean (266 seconds / 4.43 min) during a particular day were 
removed from the analysis (20 instances out of 1120, or 1.8%, across all 8 weeks).  These 
exclusions were distributed across doses, with 6/5/7/2 exclusions for control/0.2/20/2000 
ng/day doses respectively.  
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Figure 2.5: The effect of MCP-1 on body weight. 
Chronic ICV infusion of MCP-1 had no effect on the body weight of the animals across 4 weeks 
of drinking (P=0.58, n=7/6/7/8 for control/0.2/20/2000 ng/day doses respectively).  A summary 

























Figure 2.6: The effect of MCP-1 on locomotor activity. 
Chronic ICV infusion of MCP-1 had no effect on locomotor activity during drinking sessions 
(P=0.58, n=6/5/6/7 for control/0.2/20/2000 ng/day doses respectively).  A summary of 



























Figure 2.7: The effect of MCP-1 on the time to reach the response requirement. 
There was no effect on the time to reach the response requirement (4 lever presses to gain 
access to the ethanol solution) across the four weeks of drinking (P=0.88, n=7/6/7/8 for 
control/0.2/20/2000 ng/day doses respectively).  A summary of the data averaged across 
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On the final day of pump flow (35 days after pumps were filled, at the end of the 4th week 
of ethanol self-administration), a progressive ratio test was administered.  There was no 
effect on the consumption of ethanol during a progressive ratio test performed on the last 
day of pump delivery of MCP-1 (Figure 2.8, F3,23=0.33, P=0.80, one-way ANOVA, 
n=7/5/7/8 for control/0.2/20/2000 ng/day doses respectively).  There was no effect on the 
break point reached during the progressive ratio session (Figure 2.9, F3,23=0.39, P=0.76, 
one-way ANOVA, n=7/5/7/8 for control/0.2/20/2000 ng/day doses respectively).  One 
animal didn’t make the progressive ratio analysis because of infection. 
 
MCP-1 did not influence ethanol withdrawal-induced anxiety. 
 
On the final day of pump flow, 6-8 hours after the progressive ratio test was 
administered, animals were tested for ethanol withdrawal-induced anxiety.  During the 
progressive ratio session, animals had an average intake of 0.83 +/- 0.06 g/kg, which was 
evenly distributed across doses as indicated by Figure 2.8.  During the five-minute anxiety 
test session, animals were paired with an unfamiliar animal matched by dose.  There was 
no effect of dose on social interaction during the test (Figure 2.10, F3,20=1.11, P=0.37, one-
way ANOVA, n=6/4/6/8 for control/0.2/20/2000 ng/day doses respectively).  Three 
animals were excluded because they did not have a matched-dose partner at the time of the 
test.  There was no effect of dose on locomotion during the test (Figure 2.11, F3,20=0.75, 
P=0.54, one-way ANOVA, n=6/4/6/8 for control/0.2/20/2000 ng/day doses respectively).    
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Figure 2.8: The effect of MCP-1 on the ethanol intake during progressive ratio. 
There was no effect on the consumption of ethanol during a progressive ratio test 
performed at the end of the 4th drinking week (P=0.80, n=7/5/7/8 for control/0.2/20/2000 


























Figure 2.9: The effect of MCP-1 on the break point during progressive ratio. 
There was no effect on the break point reached during the progressive ratio session 

















Figure 2.10: The effect of MCP-1 on social interaction during withdrawal. 
During a five-minute session, animals were paired with an unfamiliar animal matched by 
dose.  There was no effect of MCP-1 on social interaction during the test (P=0.37, 

























Figure 2.11: The effect of MCP-1 on locomotor activity during withdrawal. 
During a five-minute session, animals were paired with an unfamiliar animal matched by 
dose.  There was no effect on locomotion during the test (P=0.54, n=6/4/6/8 for 
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Stability of MCP-1 during ICV infusion. 
 
ELISA was used to determine the concentration of MCP-1 in the pumps after 14 
days (one week after drinking began) and 28 days (3 weeks after drinking began).  Pumps 
were taken from drinking animals that were sacrificed at the day of testing (drinking data 
not reported because they didn’t meet the 4-week criteria for the ANOVA).    Data are 
expressed as a percent of the original concentration of 54 nM (2 ng/day pumps).  There 




Histological examination confirmed that cannula broke through the corpus 
callosum into the lateral ventricle in all but one animal, which was discarded from the 
analyses.  Ten placements in the ethanol experiment and two placements in the sucrose 
experiment penetrated through the ventricle into the fimbria of the hippocampus or the 
dorsal striatum and were included in the analyses because flow into the ventricle should 




Data suggesting that proinflammatory neuroimmune signaling plays a role in 
unhealthy drinking behaviors has been mounting, but the mechanisms that may contribute   
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Figure 2.12: The stability of MCP-1 during chronic infusion. 
ELISA was used to determine the concentration of MCP-1 in the pumps after 14 days (one 
week after drinking began) and 28 days (3 weeks after drinking began).  Data is expressed 
























are not completely clear.  Our results provide the first evidence of a specific cytokine 
increasing the self-administration of ethanol.  In this experiment, chronic ICV infusion of 
MCP-1 did not influence the acquisition of sweetened ethanol self-administration (across 
the first week) but increased consumption across the first 4 weeks (while MCP-1 pumps 
were flowing) and across the 8-week experiment.   The effect of MCP-1 on self-
administration developed over several weeks of infusion and several weeks of 
consumption, with the highest dose of MCP-1 (2 µg/day) yielding the highest consumption 
during weeks 3 through 8, an effect that persisted for several weeks after MCP-1 delivery 
ended.  These data suggest that increases in MCP-1, whether due to ethanol or various other 
neuroimmune mechanisms, promotes further ethanol consumption. 
Due to a paucity of published data using ICV MCP-1 infusion, particularly chronic 
infusion, it was necessary for our experiment to test a wide range of MCP-1 concentrations.  
Since only the highest dose yielded a sustained effect, our experiments may have been 
limited by the dose or stability of MCP-1.  Experiments with higher doses of MCP-1 are 
necessary to confirm and extend our results, with the possibility that higher doses or 
increased stability would yield a more robust increase in drinking or a longer-lasting effect.   
Chemokines, including MCP-1, participate in a variety of “normal” brain functions 
in addition to inflammation and pathology (for a review, see Réaux-Le Goazigo et al., 
2013).  The hallmarks of neuroinflammation are microglial activation, leukocyte 
infiltration, and blood-brain barrier (BBB) permeability, each with potentially deleterious 
consequences.  MCP-1 by itself does not activate microglia but does regulate microglial 
chemotaxis, leukocyte infiltration, and BBB permeability (Hinojosa et al., 2011; Gunn et 
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al., 1997).  MCP-1 alters BBB permeability in vivo through direct effects on endothelial 
CCR2 receptors and subsequent tight junction modification, as well as indirectly through 
the recruitment of monocytes which can then release additional MCP-1 to alter 
permeability (Stamatovic et al., 2005; Cushing and Fogelman, 1991; Tieu et al., 2009, 
Gunn et al., 1997).  An acute injection of 1 µg caused a very localized breakdown of the 
blood-brain barrier in hippocampal tissue (Bell et al., 1996) and a 25 µg ICV bolus injection 
(but not 5 µg – 20 µg) led to BBB permeability as measured by FITC-albumin leakage and 
leukocyte infiltration detected throughout the brain (Stamatovic et al., 2005).  It is difficult 
to translate bolus injections quantities to chronic pump infusion rates, but Stamatovic and 
colleagues (2005) also used chronic ICV administration of 5 µg/h for 3 days or 2.5 µg/hr 
for 7 days to achieve BBB permeability and leukocyte infiltration to a degree comparable 
to those seen with the 25 µg bolus, which are 30-fold and 60-fold higher concentrations 
than we used in our experiment.  Thus, it is unlikely that our effect on ethanol consumption 
was due to neuroinflammatory mechanisms.  Although an experiment to determine if using 
a higher dose of MCP-1 could lead to a stronger effect on ethanol consumption is 
warranted, measurements of leukocyte infiltration, BBB permeability, microglial density 
and activation, and brain MCP-1 levels, each at various points in time throughout the study, 
would help determine if MCP-1 would be facilitating ethanol consumption through normal 
or inflammatory mechanisms.   
We speculate that MCP-1 is having a neuromodulatory effect on the rewarding or 
aversive properties of ethanol consumption or withdrawal, respectively.  One possible 
“normal” mechanism in line with the concentrations of MCP-1 used in our experiment is 
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the activation of CCR2 receptors on dopamine neurons.  An intracranial injection of 50 ng 
of MCP-1 into the substantia nigra resulted in elevated dopamine levels in the dorsal 
striatum for 2 hours (measurements were taken every 20 minutes; Guyon et al., 2009).  The 
same study also showed an increase in dopaminergic activity in slices exposed to 10 nM 
MCP-1, through modulation of potassium currents.  A 50 ng bolus ICV injection also 
resulted in an increase in phosphorylated tyrosine hydroxylase levels in the VTA 24 hours 
later, while a CCR2 antagonist attenuated the conditioned place preference for 
methamphetamine (Wakida et al., 2014).  It will be critical to determine if MCP-1 levels 
reached in our experiment, or through ethanol administration alone, can influence 
dopaminergic activity.  The modest influence of MCP-1 on self-administration in our 
experiment parallels the modest influence of MCP-1 on dopamine seen in these studies.  
These parallel effects are consistent with a dopamine link in the mechanism of MCP-1 on 
sweetened ethanol consumption. 
We used sweetened ethanol in our experiment in order to maximize the success rate 
of ethanol self-administration induction and to provide consistently high levels of self-
administration in a minimal amount of time.  Minimizing induction time was critical in 
order to study both the acquisition and maintenance of self-administration during limited 
access sessions within the time-frame of MCP-1 delivery through the osmotic minipumps.  
The higher intake achieved with the addition of sucrose to the solution (1.0 g/kg with 
sucrose versus 0.6 g/kg without sucrose in a 20-minute limited-access session is common) 
increases the likelihood of central pharmacological effects of ethanol.  We have previously 
detected increased mesolimbic dopamine release within the first few minutes of intake 
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using this model (Carillo and Gonzales, 2011; Howard et al., 2009), leading us to believe 
that the BAC range reached (~0.05 % BAC) is reinforcing.  Others have shown that low 
BAC’s are anxiolytic and reinforcing as well (for a review, see Koob 2004).  Although we 
acknowledge the presence of sucrose as a complication, the lack of effect on sucrose self-
administration leads us to believe that the interaction was primarily driven by ethanol. 
Breese et al. (2008) previously did not show an increase in ethanol intake after two 
acute ICV injections of 100 ng MCP-1 or other cytokines, or various doses of 
lipopolysaccharide (LPS).  The ethanol intake model was 5 days of 4.5% ethanol liquid-
only diet, which corresponds to the timing of (and lack of effect during) our acquisition 
experiment.  We are not surprised by the lack of immediate effect in either study, given the 
protracted nature of both clinical or animal models of ethanol-induced neuroimmune gene 
expression or neuroinflammation (Qin et al., 2008; He and Crews, 2008; Valles et al., 2004; 
Pascual et al., 2007; Pascual et al., 2015; Zou and Crews, 2012; Alfonso-Loeches et al., 
2010; Erlich et al., 2012) or neuroimmune-induced increases in self-administration 
(Blednov et al., 2011).  However, comparisons of intake between our operant model and 
the 4.5% ethanol liquid-only diet used by Breese et al. (2008) should be made with caution 
due to the forced nature of ethanol consumption in the liquid-only model.  Further 
experimentation using chronic dependence models is warranted.   
In the same experiment, Breese et al. (2008) showed an increase in withdrawal-
induced anxiety after two weekly ICV injections of 100 ng MCP-1 followed by 5 days of 
a 4.5% ethanol liquid-only diet.  Their experiment did not show increased anxiety during 
withdrawal unless cytokines were administered and previously showed increased anxiety 
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only after repeated withdrawals (3 cycles) or restraint stress (Breese et al., 2004).  They 
recorded blood ethanol levels at the start of withdrawal from the 5-day ethanol diet between 
0.10 – 0.12 % BAC (Breese et al., 2004).  The average BAC after our progressive ratio 
operant session (0.86 g/kg) would be approximately 0.04 % BAC (Carillo and Gonzales, 
2011; Howard et al., 2009), which may have been too low to sensitize withdrawal anxiety.  
Additionally, our animals were dual-housed, in contrast to the single-housed method 
employed by Breese and colleagues (2004; 2008).  However, our animals were paired with 
an unfamiliar partner and our control animals matched the anxiety levels of the control 
animals in Breese et al. (2004; 2008).  Taken together, the data from our experiment and 
Breese et al. (2004; 2008) suggest that neither acute nor chronic MCP-1 cause anxiety, and 
likely exacerbate alcohol withdrawal-induced anxiety only after moderate or greater BAC.  
The apparent anxiolytic effect of low-dose MCP-1 in our experiment deserves further 
exploration, particularly in a model of alcohol dependence.   
In summary, we discovered that neuroimmune signaling through a specific 
cytokine can increase the consumption of sweetened ethanol in Long-Evans rats.  Our data 
suggest that ethanol-induced increases in MCP-1, or increases in MCP-1 due to various 
other neuroimmune mechanisms, may further promote ethanol consumption.  Our data add 
to a growing body of evidence implicating neuroimmune signaling in alcohol use disorders.  
Continued research into this mechanism, particularly using models of alcohol dependence, 
will help determine if targeting MCP-1 signaling has therapeutic potential in the treatment 
of alcohol use disorders.   
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This chapter will describe my efforts to use ethanol vapor to induce dependence in 
rodents, with the goal of using dependence to escalate voluntary drinking in a home cage 
model of self-administration.  Vapor inhalation has been shown to increase alcohol 
drinking in various animal models.  I have built ethanol vapor inhalation chambers that 
could be used to create dependent animals.  However, I had trouble obtaining blood alcohol 
levels within my target range of 0.15 % to 0.25 %, particularly for consecutive days.  
Changes in ethanol metabolism seemed to occur not only with repeated vapor exposure (in 
some rats) but also as the rodents aged and gained weight, and these changes were not 
linear.  However, reliable data was obtained with older rats (>325 g) and when using 4-
methylpyrazole to block ethanol metabolism by alcohol dehydrogenase (ADH).  I have 
also replicated a common home cage drinking model.  Both the vapor inhalation data and 








The definition of “addiction” isn’t universal.  Even the DSM criteria used by 
psychiatrists has gone through several revisions over the years and is still being contested 
today.  For example, the DSM-V, which was published in 2013, eliminated the distinction 
between alcohol abuse and alcohol dependence and combined them into “alcohol use 
disorder” with various degrees of severity (2-3 symptoms = mild, 4-5 = moderate, 6+ = 
severe).  However, what’s clear is that drug intake does not equate to drug abuse or drug 
addiction.  The brain circuitry and mechanisms influencing casual or intermittent alcohol 
intake, even binge alcohol intake, are likely very different from those influencing intake 
during addiction, and medication development is currently primarily concerned with the 
pathological states of addiction.  Although animal models of casual or binge intoxication 
are useful, models of addiction can provide additional evidence to motivate the large 
financial investments required for human clinical trials. 
 
“Dependence” can be defined by the physical adaptations that occur with repeated 
exposures to drugs and “physical dependence” is most often associated with the presence 
of withdrawal symptoms and/or the development of tolerance.  “Addiction”, sometimes 
colloquially referred to as “mental dependence”, is associated with compulsive, 
uncontrollable behaviors despite negative consequences.   Rodents will voluntarily drink 
alcohol daily, with some strains capable of reaching intoxication in a daily "binge" (BAC 
> 0.08 %) but they do not commonly voluntarily drink alcohol to the extent that is defined 
 69 
by "abuse", “addiction”, or "dependence", with the exception of those selectively bred for 
ethanol intake (e.g. “P” rats).  Therefore, when modeling addiction or dependence in a 
rodent, alcohol exposure is generally forced upon the rodent.  Further distinction can be 
made when describing whether dependence is induced when the alcohol is involuntarily 
forced upon the rodent by the experimenter (e.g. ethanol vapor, etc) or if the rodent is 
forced to voluntarily consume the drug (e.g. ethanol diet).  In this document, the term 
“dependence” refers specifically to the state of physical dependence after repeated 
exposure to a drug, to distinguish and emphasize the involuntary nature of the dependent 
state in forced-exposure animal models.  Although the brain circuitry and mechanisms 
between voluntary and involuntary models are undoubtedly different, the information 
gained from studies of dependence are extremely valuable.  Furthermore, it’s possible that 
a medication that does not influence a model of binge alcohol intake could have an effect 
on a model of dependence, and vice versa, so negative results in one model shouldn’t rule 
out experimenting with the other or considering the medication for clinical trials. 
 
One practical - yet still imperfect - way to study the brain circuitry of dependent 
animals is to first induce dependence and then pharmacologically manipulate voluntary 
intake during withdrawal.  Even if the experimenter has forced the animal to become 
dependent on a drug, the animal will still voluntarily consume the drug, particularly in 
withdrawal, and likely to a greater extent than they otherwise voluntarily would when not 
dependent.  This procedure is commonly used when studying alcohol intake; animals are 
made dependent through the forced intake of alcohol, and then the voluntary intake of 
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alcohol during withdrawal is measured and pharmacologically manipulated (for a review, 
see Vendruscolo and Roberts, 2014). 
 
There is evidence of neuroimmune signaling being enhanced after both acute and 
chronic ethanol exposure.  However, a majority of evidence has been gained from the study 
of chronic exposure, including clinical or animal models of ethanol-induced neuroimmune 
gene expression or neuroinflammation (Qin et al., 2008; He and Crews, 2008; Valles et al., 
2004; Pascual et al., 2007; Pascual et al., 2015; Zou and Crews, 2012; Alfonso-Loeches et 
al., 2010; Erlich et al., 2012) or neuroimmune-induced increases in self-administration 
(Blednov et al., 2011).  Therefore, I originally planned to use animal models of dependence 
in addition to non-dependent ethanol self-administration to research MCP-1 signaling.   
 
Vapor exposure is a preferred method of forcing alcohol exposure for inducing 
dependence in a rodent.  It is a non-invasive procedure that allows precise control over the 
dose, duration and pattern of exposure.  Evidence that chronic ethanol vapor exposure can 
increase ethanol self-administration in Wistar rats can be found in Gilpin et al. (2008), 
Gilpin et al. (2009), O'Dell et al. (2004), Richardson et al. (2008), Roberts et al. (1996), 
Walker and Koob (2007), Funk et al. (2006), and Funk et al. (2007).  Our goal was to 
induce ethanol dependence in Long-Evans rats over 4-8 weeks following the protocol of 
Funk et al. (2006) and to determine if chronic MCP-1 infusion or chronic CCR-2 antagonist 
infusion would influence self-administration of ethanol during withdrawal.  Two 
experiments were planned.  The first experiment was to test the ability of MCP-1 or the 
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CCR-2 antagonist infusion to influence the escalation of self-administration and would 
therefore be administered prior to vapor exposure.  The second experiment would test the 
ability of MCP-1 or MCP-1 antagonist to influence self-administration in already-
dependent rodents and would, therefore, begin after the animals were made dependent.  The 
formal goal of the former would be to investigate the importance of cytokine signaling in 
the development of dependence while the formal goal of the latter would be to provide 
direct evidence that MCP-1 could be targeted as a potential therapeutic mechanism to treat 
alcohol use disorders.  However, as previously mentioned, experiments with MCP-1 or the 




Ethanol dependence will be induced using a well-established model that 
incorporates chronic exposure to ethanol vapor with operant self-administration.  The 
model we plan to use in particular was developed by the laboratory of George Koob, and 
the technique details can be found in Gilpin et al. (2008) and Funk et al. (2007).  In short, 
animals spend 24 hours per day in chambers that have continuous air flow and intermittent 
alcohol flow.  Ethanol vapor concentration can be adjusted to reach desired blood alcohol 
concentrations.  Generally, alcohol vapor is cycled on for 14 hours a day and off for 10 
hours a day, with a target blood alcohol concentration of 150 to 200 mg% at the end of the 
exposure session.  Evidence that this model is more effective at increasing self-
administration than continuous vapor exposure can be found in O’Dell et al. (2004).  The 
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intermittent exposure method also provides a convenient daily withdrawal window to 
measure self-administration.  Vapor exposure normally continues for 6 to 12 weeks.  Self-
administration sessions will begin after 1 week of vapor exposure and will be performed 6 
hours into withdrawal (i.e. 6 hours into a regularly scheduled 10 hour “off” phase) either 
once or twice per week. 
 
Acrylic chambers measuring 2’x2’x2’ were designed by our lab and manufactured 
by a local company (Regal Plastics, Austin, TX).  Two standard rat cages fit in each 
chamber, and rodents may be single or dual-housed depending on the study design (home 
cage drinking animals must be single-housed in order to associate liquid lost from a bottle 
with a specific animal).  ¼” PVC tubing is used to pump air and ethanol vapor into the 
chambers and 1” PVC tubing is used to exhaust from the chambers into the fume hood to 
ensure human exposure is minimized.  Two HK-40L air pumps (Matala, Laguna Hills, CA) 
are used, one to pump fresh air continuously at 5 L/min into each chamber, while a second 
is used to pump alcohol vapor at variable rates and is turned on/off using a timer 
(Illustration 1).  A third pump and a second timer were also installed later, which pumps 
additional air, and is turned on when the ethanol vapor flow is turned off.  This keeps the 
total air/oxygen flow constant and increases clearance of ethanol from the chambers after 
the ethanol vapor flow is turned off.  Ethanol vapor is created by pushing air bubbles 
through ethanol liquid in a large container.  I experimentally determined that using a 
minimum of four 1-gallon containers and keeping them at least 75% full was required for 
consistent vapor concentrations for our 5-chamber setup.  Each 1-gallon jug was fitted with  
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Illustration 1: Vapor chamber setup. 
For most experiments, one pump continuously pumped air, while a second pump was 
switched between air and ethanol.  The setup evolved to include a 3rd pump, which was 
dedicated to air, while the second pump was dedicated to alcohol.  Both the 2nd and 3rd 
pumps were on independent timers, so that when one shut off, the other turned on.  This 






a rubber stopper and a custom cap that would screw over the stopper to keep it from 
popping off.   
Two holes were drilled in the stopper, one for intake and one for exhaust, each with 
a hard plastic tube pushed through it.  The intake tube was connected to a filter/bubbling 
stone that sat at the bottom of the container with ¼” PVC tubing.  The intake was connected 
to the pump with ¼” tubing, and the exhaust was divided 5 ways to 5 flowmeters.  The air 
pump was also split 5 ways to 5 flowmeters.  Flowmeters (Cole-Parmer, Vernon Hills, IL) 
are used to adjust the flow of air and ethanol vapor individually to each chamber (2 
flowmeters per chamber, one for ethanol vapor and one for air).  I recommend 10 L/min 
flowmeters for the air and 5 L/min flowmeters for the ethanol.  Generally, 20-35 mg of 
ethanol per liter of air is used over the 14-hour exposure to reach the desired BAC in our 
rodents, which has been achieved by using between 2.5 to 4 liters per minute of ethanol 
vapor while using 5 L/min of direct air.   Surprisingly, I have not found any published data 
on the concentration of ethanol vapor used to achieve specific BAC’s in rodents.   
 
Adjusting the flow of air through the ethanol will lead to pre-determined 
concentrations of vapor, but there is variability among animals due to a number of factors 
including rates of ethanol metabolism.  Therefore, determining BAC's through 
experimentation is necessary.  Once determined, animals will be grouped based on ethanol 
metabolism rates.  We will measure blood alcohol concentrations (BAC) by taking a 
sample of blood from the saphenous vein and using a gas chromatograph with flame 
ionization detection to measure ethanol concentrations.  In general, ethanol vapor 
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concentrations are slowly increased between exposure sessions until desired BAC's are 
reached at the end of session.  Other labs (Gilpin et al., 2008; Gass et al., 2014) use a 
behavioral assessment to gauge rodent intoxication levels, but I found this difficult to do, 
particularly for my narrow target BAC range of 0.15 to 0.25 % BAC.  For example, the 
method described in Gass et al. (2014) uses the following behavioral guidelines: 
100 to 200 mg/dl BAL: rat has a staggering gait 
200 to 300 mg/dl BAL: rat has trouble staying on its feet or cannot stand at all 
300 to 400 mg/dl (or higher) BAL: rat is totally unresponsive. 
I found that dramatic sedation started to occur in animals between 300 and 400 BAL, but 
only in naïve animals.  Tolerance developed unpredictably after repeated exposures, 
resulting in some animals appearing normal even with 300 BAL.  Furthermore, assessing 
gait was difficult and didn’t seem to be a reliable marker of BAC in my rodents.  Assessing 
gait is also difficult while rats are in the chamber, especially during the light cycle when 
the rodents are generally sleeping.  Removing the animals from the chambers to assess gait 
can also result in the significant loss of ethanol vapor from the chambers when ethanol 
vapor concentrations need to be adjusted during an exposure session.  Therefore, I went 
through substantial effort to characterize the response of Long-Evans rats to alcohol vapor 
exposure over time in an attempt to predict their BAC without having to rely on a 




Vapor standards and vapor sampling 
 
Vapor standards were made by injecting known quantities of ethanol liquid (95%, 
Aaper Alcohol and Chemical Co., Shelbyville, KY) into 1-liter glass bottles with 
silicone/PTFE septa (the exact volumes were determined by measuring the amount of water 
necessary to fill the bottle).  Up to 100 uL was injected using a gastight microsyringe with 
a beveled sharp tip, which required up to 30 minutes to evaporate and equilibrate inside the 
bottle.  A 10 ml syringe with a 25 g needle was used to sample 1 mL of air from bottle 
interior through the septa, and then the syringe was pulled to the maximum volume with 
room air to dilute to within detectable limits of the GC (the order of this is critical – do not 
pull air and then ethanol vapor).  The 10+ ml of volume in the syringe were then slowly 
injected into a 2 ml GC sample vial through the septa of a loose cap, overfilling the vial 
several times over, taking approximately 5 to 10 seconds to complete.  The cap was 
tightened as the injection was nearing completion.  Four concentrations spanning the range 
of possible vapor concentrations in the chambers was used (typically 10/40/70/100 uL) and 
very consistent results were obtained with typical r2 values of 0.999.   
 
The vapor chambers were sampled in a similar way.  A Luer-lock access port was 
installed on the front of each chamber which allowed for fast and easy sampling.  The same 
syringe/needle method was used and injected into 2 ml GC sample vials with the same 
method.   
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A Bruker 456-GC gas chromatograph with a flame ionization detector and a Varian 
8200 headspace autosampler was used to quantify ethanol in vapor and vapor standard 
preparations as well as in blood and blood standard preparations.  A Solid Phase Micro-
Extraction (SPME) fiber was used to sample vial headspace with an adsorb time of 0.01 
min (0.6 s).  The stationary phase was an HP Innowax capillary column (30m × 0.53 mm 
× 1.0 μm film thickness) and hydrogen was used as the mobile phase. Resulting ethanol 
peaks were recorded using Compass CDS software from Bruker (Billerica, MA).  
 
Blood standards and blood sampling 
 
Animals were removed from the vapor chambers individually and placed under 
anesthesia (isoflurane).  Depilatory cream was used to remove hair from the upper back 
legs of the rodents.  Either the medial or lateral saphenous vein was poked with a 25 g 
needle, resulting in a pool of blood on the skin.  10 uL of blood was pipetted from the pool 
into a 2 ml GC vial that was prefilled with 90 uL of saturated saline and capped within a 
standardized amount of time.  All blood samples were taken in triplicate.  The first session, 
which required depilatory cream, took approximate 6 minutes per animal, while future 
sessions only required 3 minutes per animal, minimizing the differences in vapor exposure 
times.  When more than 5 animals were used, their entry into ethanol vapor was staggered, 
if possible (when not using the timer to begin vapor exposure).  External standards were 
made using 10 uL of known ethanol concentrations pipetted into GC vials with 90 uL of 




Some vapor experiments used 4-methylpyrazole (4MP; Sigma-Aldrich, St. Louis, 
MO) to block alcohol dehydrogenase (ADH).   Greater than 90% of ethanol metabolism is 
due to ADH, and about 75% inhibition of ADH is achieved with 1mmol/kg pyrazole (up 
to about 85% with 2mmol/kg) and about 89% inhibition with 1mmol/kg 4MP (Plapp et al., 
2015).  Not only does pyrazole and pyrazole derivatives like 4MP inhibit ADH, but alcohol 
also inhibits the metabolism of pyrazole.  4MP has a half-life of approximately 11 hours 
for 1 mmol/kg, but that turns to approximately 33 hours when administered with a 
30mmole/kg dose of ethanol IP (~1.5 g/kg; Blomstrand and Ostling, 1977).   In order to 
determine a starting point for a 4MP dose that could stabilize BAC for a 14-hour vapor 
exposure session, I used experimental evidence that a 0.88 mmol (60 mg/kg) dose of 
pyrazole was required to make a 1.5 g/kg dose of ethanol last 15 hours in a rat (Goldberg 
and Rydberg, 1969), while a dose of 1mmol/kg of 4MP would make that dose last 36 hours 
(Plapp et al., 1984). 
 
Doses of pyrazole above 80mg/kg, and up to 600 mg/kg have been shown to cause 
sedation and CNS depression beyond what is normally expected from alcohol (Rydberg, 
1969; Ferko and Babyock, 1976).  Derivatives of pyrazole such as 4MP have become more 
common because they are more potent, more specific, and less toxic than pyrazole (Deis 
and Lester, 1979; Ferko and Babyock, 1976).  We chose to use 4MP because of known 
pharmacokinetic data, increased potency and selectivity over pyrazole, less toxicity than 
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pyrazole, and were partial to 4MP because our lab has published data using 4MP in Long-
Evans rats in the past. 
 
Ethanol Metabolic Rate 
 
Ethanol metabolism rates were determined by taking consecutive blood alcohol 
measurements for several hours.  The animal was removed from animal vapor, blood was 
drawn, and the animal was placed in fresh bedding outside of the vapor chambers.  If the 
animal’s BAC was greater than zero, 1 hour later blood was drawn again.  The process was 
repeated until an animal’s BAC reached 0, or 3 hours passed (4 points), whichever occurred 
first.  Generally speaking, animals were taken out of ethanol vapor one at a time, so that 
each animal’s start point was staggered by about 2-3 minutes.  Ethanol metabolism rates 






My first goal was to show my ability to make standards and to control the 
concentration of alcohol vapor in the chambers.  I turned the air flow to 5 L/min and the 
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alcohol vapor flow to 0.2 L/min for the first chamber, 0.3 L/min for the second chamber, 
and so on and measured the vapor concentration at various time points (Figure 3.1).   
 
I realized that the concentration of ethanol may be influenced by presence of rat 
cages, including food, bedding, and possibly urine, so I determined the effect of having 
one or two rat cages in a chamber, as well as the effect of having the standard amount of 
bedding (one scoop) compared to triple the amount of bedding (3 scoops).  I used 3 L/min 
of air and 2 L/min of ethanol vapor for this demonstration.  The chamber with only one 
cage with one scoop filled the fastest, while the chamber with 2 cages, each with 3 scoops, 
filled the slowest (and thus absorbing more ethanol), and the maximum concentration 
achieved seemed to be affected likewise, although conclusions cannot be made with just  
one sample for each condition (Figure 3.2).  Interestingly, it wasn’t the quantity of bedding 
that had the biggest initial effect, but rather the surface area of the bedding, as evidenced 
by the 2 cages / 1 scoop condition filling slower than the 1 cage / 3 scoop condition.  
However, at the 15-hour time point, the 2 cages / 1 scoop condition seemed to catch up and 
eventually surpassed the 1 cage / 3 scoop condition. 
 
Similarly, the emptying of ethanol vapor from the chambers (by leaving the air flow 
on but shutting off the ethanol vapor flow) was influenced by the presence of bedding in 
the same way (Figure 3.3).  Again, surface area was key, with the 1-cage conditions 




Figure 3.1: The control of ethanol vapor concentration in the vapor chambers. 
Using 5 L/min of air and various flow rates of ethanol, I sampled the chambers at various 




Figure 3.2: The effect of bedding on ethanol concentration.   
The chamber with only one cage with one scoop filled the fastest, while the chamber with 
2 cages, each with 3 scoops, filled the slowest, and the maximum concentration achieved 
seemed to be affected likewise, although conclusions cannot be made with just one sample 




Figure 3.3:  The effect of bedding on ethanol clearance. 
Surface area was key, with the 1-cage conditions clearing the fastest and the 2-cage 





Because of the lack of data regarding ethanol vapor concentration and resulting 
BAC’s, my first experiment with rodents was to measure BAC after only brief exposures.  
Using 2.5 L/min of air and 2.5 L/min of ethanol vapor, I pre-filled the chambers overnight, 
leading to chamber ethanol vapor concentrations of 30-35 mg/L.  I measured the BAC of 
5 rodents, weighing an average of 442 ± 14 grams after 2 hours, then again after 4 hours 
and 6 hours (Figure 3.4 A/B).  5 days later, I repeated the experiment, but with blood draws 
taken after 8, 10, and 12 hours.  Finally, I repeated it a third time 5 days after that, with 
bloods drawn after 14, 18, and 22 hours.  Some animals showed a clear ethanol metabolic 
tolerance developing by the 3rd experiment, and this was evident in their behavior.  
Generally, only rats above 0.3% BAC showed a staggering gait, and none of the rats 
became unconscious during these experiments.   
 
The next step was to expose animals to consecutive days of ethanol vapor. I lowered 
the ethanol vapor concentration to 25-30 mg/L (2 L/min ethanol vapor and 3 L/min air) 
and exposed a group of 10 animals (average 464 ± 13 g) to a 14-hour exposure for two 
consecutive days, with a 10 hour “off” period.  However, after the second day the blood 
alcohol concentrations were very high (range 0.19 to 0.46 % BAC, average of 0.32 %), so 
I measured the BAC in the rodents after the 10-hour off period to see if the BAC was being 
cleared prior to the start of the next session.  Knowing that the ethanol clearance from the 
chambers was fast but incomplete, I anticipated that the animal’s BAC would drop more   
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Figure 3.4: Blood alcohol concentration over time. 
Rats weight an average of 442 grams were exposed to 30-35 mg/L alcohol vapor for 
increasing amounts of time.  The 2/4/6 hour time points were taken on day 1, the 8/10/12 
time points were taken 5 days later, and the 14/18/22 time points were taken 5 days after 
that.  Some animals showed a clear ethanol metabolic tolerance developing by the 3rd 
experiment.  Panel A shows the average and SEM, panel B shows the individual animals.  
 86 
slowly than if they were removed from the chambers altogether.  However, I did not 
anticipate the BAC to drop from 0.32 ± 0.03 % BAC to only 0.21 ± 0.03 % BAC on 
average.  The change in BAC for the individual rodents is shown in Figure 3.5.  Clearly, 
before proceeding, I had to re-evaluate the clearance of ethanol from the vapor chambers.   
 
I purchased new flowmeters to increase the maximum air and ethanol flow to the 
chambers while still keeping the ratio the same.  I once again determined the fill rate and 
empty rate of the chambers in the presence of 2 cages with 1 scoop of bedding.  I turned 
the air flow to 5 L/min and the ethanol vapor flow to 3.33 L/min.  The maximum ethanol 
vapor concentration reached was predictable based on the ratio of air to ethanol vapor, but 
the increased flow rate meant the ethanol vapor concentration increased slightly quicker  
(data not shown).  Also, the clearance of ethanol vapor was much faster, leading to 2-3 mg 
/L after 4 hours, while previously having just over 5 mg/L after 5 hours at 3 L/min air flow 
(Figure 3.6).  Previous data from a 3 L/min experiment is shown for comparison. 
 
Not being satisfied with this ethanol clearance rate, I modified the system so that 
the ethanol flow was turned into additional air flow rather than simply being shut off after 
14 hours.  This could be accomplished by purchasing a 3rd pump and a second timer that 
would turn on when the 1st timer controlling the ethanol vapor flow shuts off.  However, 
while I waited for that additional equipment to arrive, I simply installed a shunt to manually 
divert the flow from the ethanol containers directly to the chambers.  Due to decreased   
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Figure 3.5: The change in BAC for individual animals after ethanol vapor is turned off. 
After turning the vapor concentration down to 20-25 mg/L and exposing 10 rats to two 14-
hour exposure sessions (with a 10-hour break between), the rodent BACs were very high 
(range 0.19 to 0.46 % BAC).  I measured their BAC 10 hours after ethanol vapor was shut 
off, but while the rodents were still in the chambers.  The change in BAC 10 hours later 




Figure 3.6: The clearance of ethanol vapor at various air flow rates. 
I turned the air flow to 5 L/min and the ethanol vapor flow to 3.33 L/min.  The maximum 
ethanol vapor concentration reached was predictable based on the ratio of air to ethanol 
vapor, but the increased flow rate meant the ethanol vapor concentration increased and 
decreased faster.  This graph shows the clearance of ethanol after the ethanol vapor flow is 
turned off.   
  
 89 
resistance, 3.33 L/min ethanol vapor translated to approximately 4.5 L/min air flow, for a 
total of 9 L/min air flow, (previously 3 L/min before the 2nd pump was installed). 
 
Consecutive Vapor Exposures 
 
Given the variability in ethanol metabolism rates, it became clear that individual 
chamber vapor concentrations would have to be adjusted based on individual rodent 
ethanol metabolism rates.  Since rodents can be pair-housed and each chamber can fit 2 
cages, adjusting individual chambers and swapping animals between chambers can get 
complicated.  I attempted to use consecutive 14-hour exposures to bring 10 rats to within 
the ideal range of 0.15 to 0.20, with a range of 0.15 to 0.25 also being acceptable.  I used 
510 ± 13 g rats that had been drinking an average of 0.6 g/kg daily (over 1 hour) in the 
home cage for at least one month prior (but did not drink on days they were exposed to 
ethanol vapor).  The rats were exposed to three consecutive days of vapor and then had the 
weekend off (but drank in the home cage) before resuming ethanol vapor exposure for three 
more days (Figure 3.7).  I modified ethanol flow rates between exposure sessions based on 
BAC after the previous exposure session and did not changes flow rates during an exposure 
session.  Flow meters were set at 5.0 L/min air and between 3.0 – 5.0 L/min ethanol, 
resulting in ethanol vapor concentrations of 23.2 – 31.5 mg/L.  I was unable to maintain 
BAC’s within an acceptable range during those days.  However, I confirmed that most 
animals were easily clearing all of their blood ethanol within the 10-hour off periods, even 
with initial BAC’s as high as 0.35 % (data not shown).  Not surprisingly, however,   
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Figure 3.7: BAC after consecutive days of ethanol vapor exposure. 
440 g rats that had been drinking an average of 0.6 g/kg daily (over 1 hour) in the home 
cage were exposed to three consecutive days and then had the weekend off (but drank in 
the home cage) before resuming ethanol vapor exposure for three more days.  I varied the 
vapor concentration in the chambers and swapped rats between chambers based on BAC’s.  
Flow meters were set at 5.0 L/min air and between 3.0 – 5.0 L/min ethanol, resulting in 
ethanol vapor concentrations of 23.2 – 31.5 mg/L.  I was unable to maintain BAC’s within 
an acceptable range during those days.   
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there were three animals that did not clear their blood ethanol after the 4th exposure, even 
with low initial concentrations (0.15, 0.16, and 0.22), even while their cage mates (who 
had up to a 0.35 % BAC) had cleared their blood ethanol.  
 
Ethanol Metabolism and Weight 
 
Given the extreme range of BAC’s, I performed a series of experiments with the 
goal of clarifying the factors that were contributing to create such a wide range.  I had 
already alluded to the use of home cage drinkers in the vapor chambers, which was 
motivated not only by the goal of measuring the influence of vapor exposure on home cage 
drinking, but also to investigate whether regular alcohol exposure could stabilize ethanol 
metabolism rates. 
 
The first experiment I performed compared the BAC’s of two groups of 5 ethanol-
naïve rodents with dramatically different weights (274 ± 4 g and 475 ± 2 g) that were 
exposed to the same vapor concentrations.  There was one animal from each group in each 
chamber, the air flow was 5 L/min and the ethanol vapor flow was 3.33 L/min, resulting in 
all chambers having between 24 and 29 mg/L ethanol.  I measured their BAC’s after 3, 6, 
10, and 14 hours of vapor exposure and then for 3 consecutive hours after being removed 
from ethanol vapor and put into fresh bedding to determine true ethanol metabolism rates.  
After 14 hours, the two groups had dramatically different BAC’s, with the 275 g group 
averaging 0.20 % BAC, while the 475 g group averaged 0.02 % BAC (Figure 3.8).  There   
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Figure 3.8: The effect of body weight on BAC. 
Two groups of 5 ethanol-naïve rodents with dramatically different weights (275 g and 475 
g) were exposed to the same vapor concentrations.  There was one animal from each group 
in each chamber, the air flow was 5 L/min and the ethanol vapor flow was 3.33 L/min, 
resulting in all chambers between 24 and 27 mg/L ethanol).  The 275 g group had much 
higher BAC and much greater variability than the 475 g group.  However, there was no 
difference in ethanol metabolism rates, on average (n=5 per group). 
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was also substantial variability in the 275 g group but not in the 475 g group.  However, 
there was only a small difference in their ethanol metabolism rates, with the 475 g group 
having an average rate of -0.047 %/hr (± 0.010 %) while the 275 g group had an average 
rate of -0.038 %/hr (±0.003).  Again, there was a much higher variability in ethanol 
metabolism rates in the 475 g group than the 275 g group.  (Method details - When I 
recognized that the 475 g group had very low BAC’s after the 14-hour exposure, I increased 
their vapor concentration for several hours to reach an average BAC of 0.07 before 
measuring their BAC, and then again one hour later, to determine ethanol metabolism rates 
across 1 hour).   
 
After a 4-day break, I continued to expose the 275 g group for 11 more consecutive days 
to the same vapor (14 hours on, 10 hours off).  Interestingly, their average BAC decreased 
even after 4 days off, and continued to decrease at a similar rate while being exposed to 
vapor for the next 11 days (Figure 3.9).  On the final day, I compared their BAC’s to 5 
ethanol-naïve animals from the same cohort (both groups were now about 320 g).  Both 
groups had an average BAC of 0.04.   
 
I measured the ethanol metabolism rates of both the experienced and naïve 320 g 
groups and re-tested the previous 475 g group, now at 503 ± 5 g (Table 3.1).  The repeated 
exposure group had an increase in their ethanol metabolism rates, from an average of -
0.038 %/hr to an average of -0.054 %/hr (± 0.002).  Surprisingly, the naïve group had an 
average ethanol metabolic rate even higher, at -0.064 %/hr (± 0.004).  The 503 g group   
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Figure 3.9: The effect of body weight/age and repeated vapor exposure on BAC. 
The BAC of rodents declined during repeated exposures but matched those that were not 
previously exposed.  All rats were exposed to the same ethanol vapor (range 24-29 mg/L) 





Table 3.1: Ethanol metabolism rates in young and old rats. 
Some further insight into the mechanism of BAC decline can be gleaned from comparing 
ethanol metabolism rates of the rats from Figure 3.9.  Although ethanol metabolism rate 
went up in the “young experienced” group, it was even higher in the “young naïve” group.  





stayed within range of their previous measurements, with an average of -0.042 %/hr (± 
0.002).  The old “post” group (503 g, -0.042, BAC 0.00 is not shown on Figure 3.9 because 
the ethanol vapor concentrations in their chambers were slightly lower (22 mg/L).   
 
Determining the contribution of body weight to BAC is not a simple experiment.  
Comparing two groups of different weights but with the similar ethanol metabolism rate 
can be useful but may also not be very accurate.  Although I had three groups with similar 
ethanol metabolism rates, such as the young “pre” group (275 g, -0.038, BAC 0.21, Figure 
3.8) and either the old “post” group (503 g, -0.042, BAC 0.00, data not shown) or the old 
“pre” group (475 g, -0.047, BAC 0.02, Figure 3.8), I caution against drawing conclusions 
from this comparison.  Further experimentation would be necessary to clarify this 
interaction for several reasons.  First, as previously mentioned, the old “post” group did 
not have the same ethanol vapor concentration.  Second, even minor differences between 
the groups in ethanol metabolism rates might be significant over such a long vapor 
exposure.  Third, the low n’s in each group limits the reliability of the data.  Furthermore, 
several other variables would need to be accounted for and standardized, such as the gas 
exchange rate in the lungs of the animals.  Gas exchange rate is closely tied to both 
physiological respiration as well as cellular respiration.  Specifically, the bulk flow of 
ethanol into the blood will be dependent on a variety of factors, including respiratory rate, 
respiratory volume, and BAC.  Respiratory rate and volume can be influenced by the size 
of the animal, its energy expenditure (and thus the time of day), and many other factors.  
Many of these would be difficult to control.   
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Given that my goal is to obtain BAC’s within a generous range of intoxication (0.15 
% to 0.25 %), it may not be necessary to control for gas exchange, time of day, or even the 
size of the animal.  It’s likely that simply knowing the ethanol metabolic rates can be 
enough to accurately predict BAC’s after prolonged vapor exposures.  A comparison 
between ethanol metabolic rates and BAC after the 14-hour exposure session is shown in 
Figure 3.10.  A correlation was detected between ethanol metabolism rates vs. BAC’s for 
the five instances (n=24) regardless of age or exposure experience (r=0.405, p=0.049).  A 
stronger correlation is seen when comparing only across the young animals (r=0.8256, 
p=0.0002).   
 
Although ethanol metabolism rate is clearly a factor in determining BAC’s obtained 
during vapor exposure, the data is suggesting that ethanol metabolism rates increase with 
age or size in adulthood (as opposed to vapor exposure in this case) and may also decline 
in elderly rats.  Only the latter is reflected in the literature.  There is a decline in ethanol 
metabolism rates in elderly rats that is not completely explained by changes in ADH levels 
or body water content (Collins et al., 1975; Cederbaum, 2012).  However, BAC after a 
given dose of ethanol normally steadily increases as rodents grow from 150 g to 450 g 
(Bloom et al., 1982).  ADH activity also steadily increases with age, but not as quickly as 
the size of the animal, explaining the increased BAC’s reached for a given g/kg dose of 
ethanol (Bloom et al., 1982).  Therefore, the results of my experiments remain unexplained,   
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Figure 3.10: Ethanol metabolism rate contributes to BAC in vapor 
Statistical analysis of the ethanol metabolism rates compared to BAC’s on the five 
instances (n=24) from Table 1, regardless of age or exposure experience, resulted in a 
correlation of r=0.405, p<0.05. 
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but my expectation is that individual ethanol metabolism rates will explain variations in 
BAC as long as inhalation rates remain constant.  Also, there is no doubt that ethanol 
exposure can increase ethanol metabolism rates, it’s just not evident in this circumstance.  
A larger effect would undoubtedly be seen if vapor concentrations were escalated to 
maintain BAC’s at the target level.  Replications of my experiments with bigger groups of 
animals would help clarify these details. 
 
Further insight is gleaned from examining the individual changes in BAC of the 
experienced group while undergoing consecutive exposures sessions.  While the group on 
average declined at a steady pace while in vapor (or not in vapor), the individual rats 
responded very differently (Figure 3.11).  Notice the BAC of some rats increased after the 
first exposure, while the BAC of some rats increased only after many exposures, and the 
BAC of others didn’t change.  Not only is there extreme variability in BAC, there is also 
extreme variability in the changes in BAC / ethanol metabolism rates induced by exposure 
to ethanol (or as a result of aging)!  Due to the extreme variability in BAC of young rats, 
and the variability in the changes in ethanol metabolism rate due to exposure, I would not 
recommend using rats less than 325 grams for vapor experiments. 
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Figure 3.11: Individual BAC’s during repeated vapor exposure. 
While the group on average declined at a steady pace while in vapor (or not in vapor), the 
individual rats responded very differently.  Notice the ethanol metabolism rates of some 
rats increased after the first exposure, while the ethanol metabolism rates of some rats 
increased only after many exposures, and the ethanol metabolism rates of others didn’t 
change.  Flowmeters were set to 3.33 L/min ethanol and 5 L/min air, resulting in ethanol 





It’s possible that even minor differences in ethanol metabolism rates can lead to 
dramatic differences in BAC after prolonged vapor exposures.  I demonstrate this using a 
theoretical framework in Figure 3.12, where ethanol vapor is a constant positive input for 
rats of a given size (and therefore assuming similar inhalation rates), while ethanol 
metabolism through liver ADH is a constant negative/output.  Liver ADH demonstrates 0-
order kinetics above 1mM (BAC ~0.005; Cederbaum, 2012).  Differences in ethanol 
metabolism will compound over time (e.g. a difference of 0.01 % BAC/hr will lead to 




In order to clarify the contribution of ethanol metabolism rate, I used 4MP to block 
alcohol dehydrogenase.  In the first pilot experiment, my goal was to block ADH 
maximally.  I administered either 10, 41, 82, or 164 mg/kg of 4MP (where 82 mg/kg is 1 
mmol), or vehicle, intraperitoneally, to individual rats from the “old” group, now at 590 ± 
14 g, one hour before placing them in cautiously-low ethanol vapor concentrations (15-20 
mg/L).  I measured their bloods after 1 hour, then again after 2, 3, 5, and 7 hours (Figure 
3.13).  All 4 rats had very similar BAC trajectories, so only the average is shown, with the 
vehicle animal shown separately with a BAC of 0.00 the entire time.  I also measured their 
bloods after being pulled out of vapor into fresh bedding after 1 hour, then again after 2, 3,   
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Figure 3.12: Theoretical impact of ethanol metabolism rates to BAC. 
It’s possible that even minor differences in ethanol metabolism rates can lead to dramatic 




Figure 3.13: High-dose 4MP on BAC during vapor exposure. 
A group of 5 rats weighing an average of 590 g received various high doses of 4MP (10 – 
164 mg/kg), with one rat receiving only vehicle, and were then placed in low 
concentrations of ethanol vapor (15-20 mg/L).  All rats had very similar BAC trajectories. 
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and 16 hours (Figure 3.14).  The individual values at the 7-hour point from Figure 3.13 are 
shown as the “0-hour” point in Figure 3.14.  By stabilizing ethanol metabolism rates, I was 
able to obtain reliable and predictable BAC’s in my rodents.   
 
With some clarity regarding the contribution of ethanol metabolism rate and a 
predictable escalation of BAC in vapor with doses as low as 10 mg/kg, my next goal was 
to determine the lowest dose that would allow predictable escalation while wearing off in 
time to allow ethanol to be cleared before the next exposure began.  Using 5 of the “young” 
animals, now at 477 ± 33 g, I gave them various low doses of 4MP (5, 2.5, 1, 1, and 0.5 
mg/kg) IP one hour before placing them into the same low-dose ethanol vapor (15-20 
mg/L).  I measured their BAC after 4, 7, and 14 hours of vapor exposure (Figure 3.15).  
After 14 hours of vapor exposure, I pulled them out of vapor and put them into fresh 
bedding and measured their BAC after 10 more hours.  Notice that the 5 mg/kg and 2.5 
mg/kg of pyrazole led to similar BAC after 7 hours as the high-dose animals in Figure 3.13, 
and both of those animals cleared their ethanol 10 hours later.  Finally, I was able to reliably 
bring animals to within my target BAC of 0.15 – 0.20 %! 
 
Although predictable BAC’s were obtained with the use of 4MP, matching the 
animal weights and vapor concentrations used for the previous experiments would help 
answer questions about the contributions of ethanol metabolism rate to BAC while in vapor 
and test the theoretical model.  Particular value would be gained from an experiment using 
4MP in large versus small/adolescent rodents.  Since MCP-1 or CCR2 antagonist   
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Figure 3.14: Metabolism of ethanol after various high doses of 4MP. 
Individual BAC’s after being pulled out of vapor and placed into fresh bedding.  The lowest 





Figure 3.15: BAC after various low doses of 4MP. 
Individual BAC’s of “young” animals (now 477 g) exposed to 14 hours of ethanol vapor 
(15-20 mg/L) and then pulled out of vapor and put into fresh bedding for 10 more hours. 
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experiments would involve the use of osmotic minipumps for chronic administration, 
filling the minipumps with a cocktail of pyrazole and MCP-1 or CCR2 antagonist could be 
one way to avoid daily pyrazole injections but would likely lead to animals not clearing 
their BAC during the “off” period, so a continuous exposure model would have to be 
considered, such as the one used in O’Dell et al. (2004).  Nonetheless, the use of Long-
Evans rats in vapor exposure models seems to be more complicated than using Wistar or P 
rats (Gilpin et al., 2008; Gilpin et al., 2008b).   
 
HOME CAGE DRINKING MODEL 
 
Animal models of alcohol abuse that are characterized by an escalation in voluntary 
alcohol intake to intoxicating blood alcohol levels offer a valuable research tool for 
scientists.  Our lab has put considerable effort into finding a suitable model of home-cage 
drinking without the use of sweetener.  Although operant models of self-administration, 
which require rodents to press a lever to gain access to an ethanol solution, have more face 
validity as an animal model of human alcohol consumption, home cage models offer the 
advantage of being higher-throughput since they aren’t limited by the number of operant 
chambers in the lab.  I was interested in developing a reliable model of limited-access (30 
minute) home cage drinking to maximize the throughput of experiments using ethanol 
vapor inhalation to escalate drinking.  As previously mentioned, animals that become 
dependent on ethanol through vapor inhalation reliably escalate their ethanol intake during 
the 10-hour withdrawal periods.  Several labs have used operant models to test escalations 
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in vapor dependence-induced drinking, but I have only found one other publication that 
used ethanol vapor to escalate home cage drinking (Sommer et al., 2008).  My goal was to 
administer MCP-1 or the antagonist, ICV, to influence dependence-induced escalations in 
home cage drinking. 
 
Several types of voluntary ethanol intake models exist, with variations occurring in 
ethanol access (e.g. continuous or intermittent), rodent strain, age of onset, and percentage 
of ethanol in the solution.  Our lab was interested in replicating a common model of home 
cage, intermittent (MWF), 24-hour, 2-bottle choice ethanol access design in young adult 
male Long-Evans rats using a 20% ethanol solution.  Typically, experiments performed 
using these criteria will result in rodents drinking 5–6 g/kg after 3 to 4 weeks, with 20% of 
rodents falling below a 3.5 g/kg cutoff (Simms et al., 2008; Carnicella et al., 2008; 
Carnicella et al., 2009; Carnicella et al., 2010; Ahmadiantehrani et al., 2011; Barak et al., 
2011; Nielsen et al., 2012; Hwa et al., 2013; Meyer et al., 2013; Li et al., 2012).  After 
establishing stable drinking levels, we would then use limited access sessions to teach the 
rodents to drink within a short time-frame in order to maximize blood alcohol levels and 
to allow experimental manipulation during specific time frames.  These sessions would 
typically last 30 minutes or 1 hour.  We also tried using a 15% ethanol solution.  Ethanol 
concentration can be critical; if the concentration is too high, the taste is aversive.  Many 
labs report 15% or 20% ethanol lead to the highest amounts of ethanol consumption.  
Although some rats can benefit from having the ethanol concentration escalated, we 
maintained the rodents in these experiments on a constant concentration of ethanol.    
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Comparing three replications using 20% ethanol (total n=20) with two replications 
using 15% ethanol (total n=12), during the first 12 sessions, the 20% groups escalated their 
intake faster than the 15% groups (F11,327 = 1.85, P<0.05).  During week 4, the 20% groups 
averaged 3.01 ±0.24 g/kg while the 15% groups averaged 1.88 ±0.24 g/kg (P<0.005).  Only 
a fraction of our animals (28%) reached the typical cutoff of 3.5 g/kg during the 4th week.  
After reaching stable drinking levels, a subset of animals were given limited-access to 
ethanol (60 minutes).  Drinking levels peaked near 0.7 to 0.8 g/kg for all groups.  Although 
our data did not replicate previously published data by other labs (in terms of max g/kg 
achieved), it was reliable enough to move forward.   
 
I replicated the home cage experiment with a large cohort of young adult animals (starting 
at 200g), using only 20% ethanol.  Initially, rodents were given 24-hour access on M/W/F, 
with 29 rodents having 24-hour access for 11 sessions before being switched over to 1-
hour access, while 17 of the 29 had 24-hour access for 15 sessions before being switched 
over to 1-hour access (Figure 3.16).  1-hour access was measured the entire time, but bottles 
were immediately put back during 24-hour access sessions.  The first day of 1-hour-only 
access corresponds to session 16 for all animals.  Although not reaching the g/kg typically 
seen in the literature during 24-hour access, my values generally matched those of the lab’s 
20% experiments described above.  Although these animals were not chronically exposed 
to ethanol vapor, a few were exposed for up to 6 sessions (previously shown in Figure 3.7).  
The recommended next step would be to determine if these animals would reliably escalate   
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Figure 3.16: Home cage drinking experiment. 
A cohort of 29 male Long-Evans rats weight approximately 200 g had access to ethanol in 
their home cage for 24 hours on M/W/F.  Ethanol consumption was measured at 1 hour 
and at 24 hours.  After 11 or 15 sessions, animals were switched to 1-hour access only.  
The first day of 1-hour access starts on session 16 for all animals in this graph for 
illustrative purposes.   
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their limited-access home cage drinking while becoming dependent on alcohol through 




This chapter described my efforts to induce ethanol dependence in animals using 
repeated ethanol vapor exposures, as well as my efforts to develop a home cage ethanol 
drinking model.  The goal of these experiments were to reliably increase home cage 
drinking in dependent animals and then manipulate drinking by using MCP-1 or the CCR2 
antagonist.   
 
I was not able to obtain BAC’s within my target range using ethanol vapor for 
consecutive days unless 4MP was used to block alcohol metabolism.  It seems that 
individual differences in ethanol metabolic rates contributes to variability in BAC in 
ethanol vapor (although, it is not the only variable).  Ethanol metabolic rates seem to 
increase as the animals aged, as well as with repeated bouts of high BAC-inducing 
exposures.  However, these increases were unpredictable.  It is unclear if the increase in 
ethanol metabolic rate seen when the animals aged was simply due to the increase in the 
size of the liver.  The increase was seen up to 325 g, but animals that were 500 g had slower 
ethanol metabolic rates.  Further experimentation will be necessary to parse out the 
contributions of weight, liver size, and metabolic tolerance to BAC.  However, reliable 
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BAC’s are obtained when using 4MP, and experiments to induce dependence can move 
forward as long as 4MP is injected daily.    
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Chapter 5: Discussion and Conclusion 
 
The goals of my dissertation project were to investigate the role of MCP-1 in 
ethanol self-administration, in animal models of both dependent and non-dependent 
ethanol self-administration.  The initial plan was to investigate both the agonist and 
antagonist, but due to a variety of factors, this turned out to be over-ambitious.  I have 
presented my progress toward these goals, which included experiments investigating the 
role of MCP-1 in a non-dependent model of ethanol self-administration, the development 
of a limited-access home cage drinking model, and obtaining reliable BAC’s during ethanol 
vapor inhalation.  This work spanned approximately 3 years, from the Fall of 2012 to the 
Fall of 2015.  The first 3 years of my graduate study from the Fall of 2009 to the Fall of 
2012, culminated in a first-author paper entitled “μ-opioid receptors in the stimulation of 
mesolimbic dopamine activity by ethanol and morphine in Long-Evans rats: a delayed 
effect of ethanol” which was published in the journal Psychopharmacology (Berl) in 2013.   
 
In this chapter, I will present additional discussion that was not included in the 




One pervasive theme throughout this dissertation is the role of dopamine in drug 
abuse as well as the influence of neuroimmune signaling on dopamine neurotransmission.  
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Further discussion of this interaction is warranted, but a more formal introduction is 
necessary.   
 
Mesolimbic dopamine neurons, which originate in the ventral tegmental area 
(VTA) and project to the ventral striatum, are thought to play a role in goal-directed 
behaviors, including operant self-administration and ethanol reinforcement (for review, see 
Gonzales et al., 2004).  Activities that enhance the “survival of the species,” such as food, 
water, and sex, which are referred to as “natural reinforcers”, are powerful activators of 
mesolimbic dopamine neurons.  Natural reinforcers and most drugs of abuse are known to 
increase dopamine release in the nucleus accumbens, primarily in the “shell” region of the 
nucleus accumbens.  However, many drugs of abuse can increase dopamine 
neurotransmission to a far greater extent than the aforementioned natural reinforcers.  
Historically, mesolimbic dopamine was thought to act as a reward mechanism, serving as 
a hedonic indicator (Wise and Bozart, 1987).  However, more recent data is suggesting that 
mesolimbic dopamine serves more as a predictor of reward than a rewarding mechanism 
in itself, determining the motivation in response to a particular context (Schultz et al., 1997; 
Schultz et al., 2007).  For example, in animals that have previously learned to administer 
drugs of abuse, the dopamine increase is seen in response to the presentation of the drug 
rather than the intake of the drug itself (Schultz et al., 1997).  Even though the precise 
function of dopamine neurons is still under debate (for a review, see Salamone and Correa, 
2002), there is evidence that dopamine release is an essential component in the 
development of addictive behaviors, including drug abuse. 
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DOPAMINE AND ALCOHOL 
 
Evidence gathered through pharmacological manipulation, genetic modification, 
and direct measurement support the importance of dopamine in many aspects of ethanol-
seeking behavior.  Data from our lab and many others have shown a transient increase in 
dopamine (~30%) during operant self-administration of ethanol (Doyon et al., 2003).  Also, 
dopamine agonists can increase alcohol self-administration and the blockade of dopamine 
receptors can suppress ethanol reinforcement (Hodge et al., 1992; Rassnick et al., 1992).  
Furthermore, genetic knockout of dopamine receptors inhibits ethanol drinking (Phillips et 
al., 1998) and seeking behavior (Czachowski et al., 2001) while self-administration of 
ethanol directly into the nucleus accumbens has been reported in high-drinking rodent 
strains (Gatto et al., 1994; Rodd-Henricks et al., 2000; Engleman et al., 2009).   
 
For drugs like cocaine and heroin, the cellular mechanisms that result in increased 
dopamine neurotransmission are fairly well understood (Johnson & North, 1992; Giros et 
al., 1996).  However, the mechanism behind ethanol-stimulated dopamine release isn’t as 
clear.  Electrophysiological recordings provide evidence that ethanol can increase the firing 
rate of dopamine neurons in vivo and in vitro (Gessa et al., 1985; Brodie et al., 1999; 
Okamoto et al., 2006).  However, the molecular mechanisms leading to that increase are 
still being sorted out.  Nonetheless, it’s clear that dopamine is important in self-
administration, including the self-administration of ethanol. 
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MCP-1 AND DOPAMINE 
 
Chemokines can influence neurotransmission through a variety of mechanisms, 
including through the modulation of neurotransmitter receptors or neurotransmitter release 
itself (Gosselin et al., 2005; Rostene et al., 2007; Guyon et al., 2009).  As previously 
mentioned, MCP-1 increases dopamine release (Guyon et al., 2009) likely due to MCP-1 
modulation of potassium channels (Guyon et al, 2009; Apartis et al, 2010; Wakida et al., 
2014).  A 50 ng bolus ICV injection also resulted in an increase in phosphorylated tyrosine 
hydroxylase levels in the VTA 24 hours later, while a CCR2 antagonist attenuated the 
conditioned place preference for methamphetamine (Wakida et al., 2014).  How exactly 
MCP-1 influences dopamine release is still unclear, and may involve CCR2 activation of 
intracellular cascades that could influence potassium channel inactivation or 
internalization.  Interestingly, the effect of MCP-1 on dopamine neurons is delayed several 
minutes, while wash-out effects are much faster (Guyon et al., 2009).  Nonetheless, further 
experimentation is warranted to figure out these details. 
 
CRF INCREASES MCP-1 SIGNALING IN THE VTA 
 
As previously mentioned, stress hormones are thought to play a major role in the 
transition to alcohol dependence (for a review, see Heilig and Koob, 2007).  The link 
between neuroimmune signaling and alcohol use disorders grew even stronger recently 
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with the discovery that CRF-induced increases in drinking in P rats are promoted by MCP-
1 signaling in neurons of the VTA and CeA (June et al. 2015).  Furthermore, June et al. 
(2015) also noted that P rats (a strain of inbred high alcohol preferring rats) have innately 
elevated levels of MCP-1 and TLR4 that colocalize in the neurons of those regions 
(compared to non-preferring “NP” rats).  The interaction between stress and immune 




Alcohol, other drugs of abuse, stress, and immune signaling are all known to 
influence synaptic function, neuronal excitability, and influence reward system function.  
Furthermore, all of these also (further) increase neuroimmune gene expression or signaling.  
This has led to several researchers forming the hypothesis that neuroimmune loops drive 
addiction (Crews et al., 2011; Mayfield et al., 2013; Cui et al., 2014).  A simplified 
schematic highlighting the role of MCP-1 and TNFα in the propagation of neuroimmune 
gene induction and neurotoxicity is shown in Figure 5.1 (adapted from Zou and Crews, 
2010).  Neuroimmune influences on all three stages of addiction, including 
binge/intoxication, withdrawal/negative affect, and preoccupation/anticipation can all be 
amplified with repeat exposures and lead to persistent effects.  Influences on reward 
circuitry, stress systems, executive control, and anxiety circuitry are all common 
denominators.  Thus, neuroimmune activation/amplification may be a critical component 
of the brain dysfunction that drives addictive behaviors.    
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Figure 5.1: Amplification of MCP-1 signaling 
Schematic highlighting the role of MCP-1 and TNFα in the propagation of neuroimmune 
gene induction and neurotoxicity.  Microglia, astrocytes, and neurons can all secrete MCP-
1 and have CCR2 receptors.  Microglia can amplify their own recruitment to a site of brain 
injury.  This phenomenon may also drive progression through the stages of addiction.  





A variety of immune receptor signaling cascades lead to the activation of the 
activator protein 1 (AP-1) and NF-kB transcription factors, which induce cell-specific gene 
transcription.  In microglia, activation of the CCR2 receptor is known to induce NF-kB 
(See Figure 1.2).   NF-kB is constitutively transcriptionally active in the brain and is central 
to the promotion of a neuroinflammatory response, including the transcription of MCP-1 
and various other cytokines.  Activated microglia or astrocytes, neurons, and infiltrating 
leukocytes will secrete additional cytokines, including MCP-1 (for a review, see Semple et 
al., 2010), resulting in an amplification of signaling (Cushing and Fogelman, 1991; Tieu et 
al., 2009; Gunn et al., 1997).  Furthermore, activated microglia, astrocytes, and neurons all 
express CCR2 receptors.  Evidence suggests that monocytes amplify their own recruitment 
to an inflammatory site, and subsequent activation, through autocrine induction of MCP-1 
(Cushing and Fogelman, 1991).   
 
This is particularly noteworthy because ethanol has be shown to cause the release 
of MCP-1 (Zou and Crews, 2010; Qin et al., 2008; He and Crews, 2008).  Additionally, 
ethanol itself, under specific conditions, is known to induce microglial activation, although 
which stage of activation is under debate (Marshall et al., 2013; Crews et al., 2006).  Given 
that our data has shown an increase in ethanol self-administration due to MCP-1 infusion, 
an effect that sensitizes over several weeks of drinking and results in persistent effects, it’s 
possible that a feed-forward mechanism is driving the increase in drinking.  A feed-forward 
mechanism could be tested by measuring MCP-1 in the brains of these animals at various 
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points in time throughout the experiment.  The hypothesis that ethanol-induced increases 




Given that MCP1/CCR2 knockout mice drink significantly less alcohol than 
controls (Figure 1.3), experiments using a CCR2 antagonist are justified.  The ability of 
CCR2 antagonists to modulate ethanol drinking behavior has never been investigated.  The 
osmotic minipump is particularly well-suited for the delivery of the antagonist.  Several 
experiments come to mind.  One would be to test the ability of the antagonist in a binge or 
non-dependent self-adnimistration model.  Another would be to prevent the escalation of 
drinking due to vapor exposure.  The goal would be to completely block MCP-1 signaling 
continuously throughout the development of dependence in order to make sure that 
transient MCP-1 signaling doesn’t occur.  A third experiment would be to investigate the 
therapeutic potential of the antagonist by administering it to already-dependent rodents. 
 
The specific brain regions involved in the MCP-1 experiments was not determined 
because ICV infusions are known to distribute throughout the brain.  Determining which 
brain regions involved in the neuroimmune regulation of drinking behavior will increase 
our understanding of the phenomenon and can lead to more selective compounds with 
fewer potential side effects.  The mesolimbic dopamine system has been identified as a 
candidate due to its importance in the regulation of drinking behavior and the presence of 
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CCR2 receptors on those neurons.  Microinjections of either MCP-1 or the antagonist into 




The results of my experiments provide critical new knowledge about a new area of 
research. By understanding how neuroimmune signaling can facilitate the acquisition or 
escalation of drinking behavior, we can develop insights into the transition from healthy to 
unhealthy drinking behavior and we can develop new molecular targets for treatment. Also, 
once we identify the key molecules involved, we could develop means of identifying those 
at high risk for the disease and take precautionary measures to help them avoid developing 
the disease, including monitoring or prophylactic treatment. Furthermore, advances in 
therapeutics for alcohol abuse can potentially translate into therapeutics for substance 
abuse in general. Our results will help motivate investigations into whether neuroimmune 
signaling can be used for the treatments for other behavioral pathologies. Finally, our data 
may have a broader scientific significance by supporting theories that complex behaviors 
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